Raras
Buscar doenças, sintomas, genes...
Doença mitocondrial
ORPHA:68380DOENÇA RARA

Doenças causadas por função anormal das mitocôndrias. Podem ser causadas por mutações, adquiridas ou herdadas, no DNA mitocondrial ou em genes nucleares que codificam componentes mitocondriais. Eles também podem ser o resultado de disfunção mitocondrial adquirida devido a efeitos adversos de medicamentos, infecções ou outras causas ambientais.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doenças causadas por função anormal das mitocôndrias. Podem ser causadas por mutações, adquiridas ou herdadas, no DNA mitocondrial ou em genes nucleares que codificam componentes mitocondriais. Eles também podem ser o resultado de disfunção mitocondrial adquirida devido a efeitos adversos de medicamentos, infecções ou outras causas ambientais.

Pesquisas ativas
10 ensaios
448 total registrados no ClinicalTrials.gov
Publicações científicas
4.060 artigos
Último publicado: 2026 Apr 16
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
211 sintomas
💪
Músculos
110 sintomas
🦴
Ossos e articulações
93 sintomas
👁️
Olhos
92 sintomas
❤️
Coração
78 sintomas
🫃
Digestivo
62 sintomas

+ 695 sintomas em outras categorias

Características mais comuns

Neuropatia sensorimotora
Função ventricular cardíaca anormal
Hiperisoleucinemia
Hipercoagulabilidade
Encefalopatia hepática
Fraqueza muscular distal progressiva
1627sintomas
Sem dados (1627)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 1627 características clínicas mais associadas, ordenadas por frequência.

Neuropatia sensorimotoraSensorimotor neuropathy
Função ventricular cardíaca anormalAbnormal cardiac ventricular function
HiperisoleucinemiaHyperisoleucinemia
HipercoagulabilidadeHypercoagulability
Encefalopatia hepáticaHepatic encephalopathy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico4.060PubMed
Últimos 10 anos200publicações
Pico2025119 papers
Linha do tempo
2026Hoje · 2026🧪 1978Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

87 genes identificados com associação a esta condição.

FHFumarate hydratase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible stereospecific interconversion of fumarate to L-malate (PubMed:30761759). Experiments in other species have demonstrated that specific isoforms of this protein act in defined pathways and favor one direction over the other (Probable) Catalyzes the hydration of fumarate to L-malate in the tricarboxylic acid (TCA) cycle to facilitate a transition step in the production of energy in the form of NADH Catalyzes the dehydration of L-malate to fumarate (By similarity). Fumarate

LOCALIZAÇÃO

MitochondrionCytoplasm, cytosolNucleusChromosome

VIAS BIOLÓGICAS (2)
Citric acid cycle (TCA cycle)Mitochondrial protein degradation
MECANISMO DE DOENÇA

Fumarase deficiency

A severe autosomal recessive metabolic disorder characterized by early-onset hypotonia, profound psychomotor retardation, and brain abnormalities, such as agenesis of the corpus callosum, gyral defects, and ventriculomegaly. Many patients show neonatal distress, metabolic acidosis, and/or encephalopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
139.4 TPM
Fibroblastos
128.8 TPM
Coração - Ventrículo esquerdo
120.5 TPM
Músculo esquelético
115.0 TPM
Fígado
104.5 TPM
OUTRAS DOENÇAS (3)
fumaric aciduriahereditary leiomyomatosis and renal cell cancerhereditary pheochromocytoma-paraganglioma
HGNC:3700UniProt:P07954
MTRFRMitochondrial translation release factor in rescueCandidate gene tested inTolerante
FUNÇÃO

Part of a mitoribosome-associated quality control pathway that prevents aberrant translation by responding to interruptions during elongation (PubMed:33243891). As heterodimer with MTRES1, ejects the unfinished nascent chain and peptidyl transfer RNA (tRNA), respectively, from stalled ribosomes. Recruitment of mitoribosome biogenesis factors to these quality control intermediates suggests additional roles for MTRES1 and MTRF during mitoribosome rescue (PubMed:33243891)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial ribosome-associated quality control
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 7

A mitochondrial disease resulting in encephalomyopathy. Clinical manifestations include psychomotor delay and regression, ataxia, optic atrophy, nystagmus and muscle atrophy and weakness.

OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 55combined oxidative phosphorylation defect type 7
HGNC:26784UniProt:Q9H3J6
IARS2Isoleucine--tRNA ligase, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Aminoacyl-tRNA synthetase that catalyzes the specific attachment of isoleucine to its cognate tRNA (tRNA(Ile))

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein degradationMitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia

An autosomal recessive disorder characterized by cataracts, short-stature secondary to growth hormone deficiency, sensorineural hearing deficit, peripheral sensory neuropathy, skeletal dysplasia, scoliosis, and facial dysmorphism.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
107.8 TPM
Linfócitos
84.2 TPM
Glândula adrenal
72.5 TPM
Artéria tibial
71.5 TPM
Tecido adiposo
69.7 TPM
OUTRAS DOENÇAS (2)
cataract-growth hormone deficiency-sensory neuropathy-sensorineural hearing loss-skeletal dysplasia syndromeLeigh syndrome
HGNC:29685UniProt:Q9NSE4
TRMT5tRNA (guanine(37)-N(1))-methyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Involved in mitochondrial tRNA methylation (PubMed:26189817). Specifically methylates the N1 position of guanosine-37 in various tRNAs. Methylation is not dependent on the nature of the nucleoside 5' of the target nucleoside. This is the first step in the biosynthesis of wybutosine (yW), a modified base adjacent to the anticodon of tRNAs and required for accurate decoding

LOCALIZAÇÃO

Mitochondrion matrixNucleusCytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of wybutosine at G37 of tRNA(Phe)
MECANISMO DE DOENÇA

Peripheral neuropathy with variable spasticity, exercise intolerance, and developmental delay

An autosomal recessive mitochondrial disorder with multisystemic and highly variable manifestations. Affected individuals suffer from a peripheral neuropathy, with distal muscle weakness and atrophy, and distal sensory impairment. Additional variable features include early-onset hypotonia and global developmental delay, poor or absent motor skills, exercise intolerance, poor growth, cerebellar signs, spasticity, and seizures. Biochemical analysis may show deficiencies in mitochondrial respiratory complex. Lactic acidosis is frequently observed.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
19.5 TPM
Fibroblastos
15.3 TPM
Linfócitos
11.9 TPM
Ovário
9.9 TPM
Nervo tibial
9.3 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 26
HGNC:23141UniProt:Q32P41
RRM2BRibonucleoside-diphosphate reductase subunit M2 BCandidate gene tested inTolerante
FUNÇÃO

Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesInterconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 8A

A disorder due to mitochondrial dysfunction characterized by various combinations of neonatal hypotonia, neurological deterioration, respiratory distress, lactic acidosis, and renal tubulopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.2 TPM
Tireoide
33.1 TPM
Fibroblastos
25.4 TPM
Aorta
22.0 TPM
Pulmão
20.7 TPM
OUTRAS DOENÇAS (7)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunctionmitochondrial DNA depletion syndrome 8aKearns-Sayre syndrome
HGNC:17296UniProt:Q7LG56
TXN2Thioredoxin, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Important for the control of mitochondrial reactive oxygen species homeostasis, apoptosis regulation and cell viability (PubMed:12032145, PubMed:12080052, PubMed:26626369) Is involved in various redox reactions including the reduction of protein disulfide bonds, through the reversible oxidation of its active center dithiol to a disulfide (By similarity)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Degradation of cysteine and homocysteineDetoxification of Reactive Oxygen Species
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 29

An autosomal recessive, infantile-onset, neurodegenerative disorder characterized by decreased activities of mitochondrial respiratory complexes I and III, severe cerebellar atrophy, epilepsy, dystonia, optic atrophy, and peripheral neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
170.2 TPM
Linfócitos
135.1 TPM
Fibroblastos
102.0 TPM
Ovário
98.4 TPM
Tireoide
95.8 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation deficiency 29
HGNC:17772UniProt:Q99757
COQ4Ubiquinone biosynthesis protein COQ4 homolog, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Lyase that catalyzes the C1-decarboxylation of 4-hydroxy-3-methoxy-5-(all-trans-decaprenyl)benzoic acid into 2-methoxy-6-(all-trans-decaprenyl)phenol during ubiquinone biosynthesis

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Ubiquinol biosynthesis
MECANISMO DE DOENÇA

Coenzyme Q10 deficiency, primary, 7

An autosomal recessive disorder resulting from mitochondrial dysfunction and characterized by decreased levels of coenzyme Q10, and severe cardiac or neurologic symptoms soon after birth, usually resulting in death. Rarely, symptoms may have later onset.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
spastic ataxia 10, autosomal recessiveneonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
HGNC:19693UniProt:Q9Y3A0
MARS2Methionine--tRNA ligase, mitochondrialCandidate gene tested inTolerante
LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Spastic ataxia 3, autosomal recessive

A neurologic disorder characterized by cerebellar ataxia, ataxic gait, spasticity, and hyperreflexia. Other variable features include dysarthria, dysmetria, mild cognitive impairment, urinary urgency and dystonic positioning.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
25.8 TPM
Esôfago - Mucosa
7.7 TPM
Baço
7.5 TPM
Fibroblastos
7.2 TPM
Glândula adrenal
7.2 TPM
OUTRAS DOENÇAS (2)
spastic ataxia 3combined oxidative phosphorylation defect type 25
HGNC:25133UniProt:Q96GW9
TRMT10CtRNA methyltransferase 10 homolog CCandidate gene tested inTolerante
FUNÇÃO

Mitochondrial tRNA N(1)-methyltransferase involved in mitochondrial tRNA maturation (PubMed:18984158, PubMed:21593607, PubMed:23042678, PubMed:27132592). Component of mitochondrial ribonuclease P, a complex composed of TRMT10C/MRPP1, HSD17B10/MRPP2 and PRORP/MRPP3, which cleaves tRNA molecules in their 5'-ends (PubMed:18984158). Together with HSD17B10/MRPP2, forms a subcomplex of the mitochondrial ribonuclease P, named MRPP1-MRPP2 subcomplex, which displays functions that are independent of the

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (3)
tRNA processing in the mitochondrionrRNA processing in the mitochondriontRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 30

An autosomal recessive, severe mitochondrial disease characterized by lactic acidosis, hypotonia, feeding difficulties, deafness, and respiratory failure with fatal issue. Patient skeletal muscle cells show decreased activities of mitochondrial complexes I, III and IV.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
45.9 TPM
Fibroblastos
39.8 TPM
Fallopian Tube
23.3 TPM
Esôfago - Mucosa
21.3 TPM
Baço
20.9 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 30
HGNC:26022UniProt:Q7L0Y3
MIPEPMitochondrial intermediate peptidaseCandidate gene tested inTolerante
FUNÇÃO

Cleaves proteins, imported into the mitochondrion, to their mature size

LOCALIZAÇÃO

Mitochondrion matrix

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 31

An autosomal recessive, severe mitochondrial disease with multisystemic manifestations appearing soon after birth or in early infancy. Clinical features include left ventricular non-compaction, global developmental delay, severe hypotonia, seizures, cataract, and abnormal movements. Death may occur in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
26.7 TPM
Skin Not Sun Exposed Suprapubic
26.3 TPM
Linfócitos
16.9 TPM
Fibroblastos
15.5 TPM
Coração - Átrio
15.4 TPM
OUTRAS DOENÇAS (1)
lethal left ventricular non-compaction-seizures-hypotonia-cataract-developmental delay syndrome
HGNC:7104UniProt:Q99797
RRM1Ribonucleoside-diphosphate reductase large subunitCandidate gene tested inAltamente restrito
FUNÇÃO

Provides the precursors necessary for DNA synthesis. Catalyzes the biosynthesis of deoxyribonucleotides from the corresponding ribonucleotides

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Interconversion of nucleotide di- and triphosphates
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 6

A form of progressive external ophthalmoplegia, a mitochondrial myopathy characterized by progressive paralysis of the levator palpebrae, orbicularis oculi, and extraocular muscles. Ragged red fibers are seen on muscle biopsy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
104.0 TPM
Fibroblastos
56.4 TPM
Skin Sun Exposed Lower leg
47.0 TPM
Skin Not Sun Exposed Suprapubic
42.4 TPM
Vagina
32.8 TPM
OUTRAS DOENÇAS (2)
progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal recessive 6autosomal recessive progressive external ophthalmoplegia
HGNC:10451UniProt:P23921
MT-TKCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromematernally-inherited cardiomyopathy and hearing lossmaternally-inherited Leigh syndrome
HGNC:7489
MT-ATP8ATP synthase F(0) complex subunit 8Candidate gene tested inDesconhecido
FUNÇÃO

Subunit 8, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (PubMed:37244256). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (3)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formation
MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, mitochondrial 2

A mitochondrial disorder with heterogeneous clinical manifestations including neuropathy, ataxia, hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy can present with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal contours/morphologies with extremely varying clinical course.

OUTRAS DOENÇAS (4)
mitochondrial diseaseperiodic paralysis with later-onset distal motor neuropathymitochondrial proton-transporting ATP synthase complex deficiencyKearns-Sayre syndrome
HGNC:7415UniProt:P03928
ETFDHElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Accepts electrons from ETF and reduces ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Respiratory electron transport
MECANISMO DE DOENÇA

Glutaric aciduria 2C

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
51.2 TPM
Fígado
43.3 TPM
Glândula adrenal
41.9 TPM
Músculo esquelético
41.7 TPM
Coração - Átrio
38.5 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, severe neonatal typemultiple acyl-CoA dehydrogenase deficiency, mild type
HGNC:3483UniProt:Q16134
ETFAElectron transfer flavoprotein subunit alpha, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Heterodimeric electron transfer flavoprotein that accepts electrons from several mitochondrial dehydrogenases, including acyl-CoA dehydrogenases, glutaryl-CoA and sarcosine dehydrogenase (PubMed:10356313, PubMed:15159392, PubMed:15975918, PubMed:27499296, PubMed:9334218). It transfers the electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase) (PubMed:9334218). Required for normal mitochondrial fatty acid oxidation and normal amino acid metabol

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Respiratory electron transport
MECANISMO DE DOENÇA

Glutaric aciduria 2A

An autosomal recessively inherited disorder of fatty acid, amino acid, and choline metabolism. It is characterized by multiple acyl-CoA dehydrogenase deficiencies resulting in large excretion not only of glutaric acid, but also of lactic, ethylmalonic, butyric, isobutyric, 2-methyl-butyric, and isovaleric acids.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
144.9 TPM
Músculo esquelético
109.5 TPM
Glândula adrenal
101.8 TPM
Coração - Ventrículo esquerdo
98.5 TPM
Fígado
90.9 TPM
OUTRAS DOENÇAS (3)
multiple acyl-CoA dehydrogenase deficiencymultiple acyl-CoA dehydrogenase deficiency, mild typemultiple acyl-CoA dehydrogenase deficiency, severe neonatal type
HGNC:3481UniProt:P13804
NDUFB3NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3Candidate gene tested inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 25

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN25 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
145.0 TPM
Linfócitos
128.5 TPM
Coração - Átrio
121.7 TPM
Músculo esquelético
120.4 TPM
Rim - Medula
112.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 25mitochondrial complex I deficiency
HGNC:7698UniProt:O43676
NDUFV2NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (Probable). Parts of the peripheral arm of the enzyme, where the electrons from NADH are accepted by flavin mononucleotide (FMN) and then passed along a chain of iron-sulfur clusters by electron tunnelling to the final acceptor ubiquinone (Probable). Contains one iron-sulfur cluster (Probabl

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 7

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN7 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
143.4 TPM
Linfócitos
138.2 TPM
Coração - Ventrículo esquerdo
111.4 TPM
Fígado
99.1 TPM
Glândula adrenal
86.0 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 7mitochondrial complex I deficiencyprogressive cavitating leukoencephalopathy
HGNC:7717UniProt:P19404
MECREnoyl-[acyl-carrier-protein] reductase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:12654921, PubMed:18479707, PubMed:27817865). May provide the octanoyl chain used for lipoic acid bio

LOCALIZAÇÃO

MitochondrionCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
MECANISMO DE DOENÇA

Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities

An autosomal recessive neurologic disorder characterized by childhood-onset dystonia, basal ganglia degeneration and optic atrophy with decreased visual acuity. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYTOABG severity is variable, and some patients lose independent ambulation.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
16.3 TPM
Nervo tibial
15.9 TPM
Útero
15.8 TPM
Cervix Endocervix
15.2 TPM
Cervix Ectocervix
14.8 TPM
OUTRAS DOENÇAS (3)
dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalitiesoptic atrophy 16obsolete autosomal recessive optic atrophy
HGNC:19691UniProt:Q9BV79
HSD17B4Peroxisomal multifunctional enzyme type 2Candidate gene tested inTolerante
FUNÇÃO

Bifunctional enzyme acting on the peroxisomal fatty acid beta-oxidation pathway. Catalyzes two of the four reactions in fatty acid degradation: hydration of 2-enoyl-CoA (trans-2-enoyl-CoA) to produce (3R)-3-hydroxyacyl-CoA, and dehydrogenation of (3R)-3-hydroxyacyl-CoA to produce 3-ketoacyl-CoA (3-oxoacyl-CoA), which is further metabolized by SCPx. Can use straight-chain and branched-chain fatty acids, as well as bile acid intermediates as substrates

LOCALIZAÇÃO

Peroxisome

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

D-bifunctional protein deficiency

Disorder of peroxisomal fatty acid beta-oxidation.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
203.8 TPM
Glândula adrenal
129.8 TPM
Fígado
119.8 TPM
Pulmão
107.4 TPM
Brain Spinal cord cervical c-1
105.2 TPM
OUTRAS DOENÇAS (3)
Perrault syndrome 1d-bifunctional protein deficiencyPerrault syndrome 2
HGNC:5213UniProt:P51659
AIFM1Apoptosis-inducing factor 1, mitochondrialCandidate gene tested inAltamente restrito
FUNÇÃO

Functions both as NADH oxidoreductase and as regulator of apoptosis (PubMed:17094969, PubMed:20362274, PubMed:23217327, PubMed:33168626). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway (PubMed:20362274). Release into the cytoplasm is mediated upon binding to poly-ADP-ribose chains (By similarity). The soluble form (AIFsol) found in the nuc

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion inner membraneCytoplasmNucleusCytoplasm, perinuclear regionMitochondrionCytoplasm, cytosol

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 6

A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy.

OUTRAS DOENÇAS (4)
X-linked hereditary sensory and autonomic neuropathy with hearing lossCharcot-Marie-Tooth disease X-linked recessive 4spondyloepimetaphyseal dysplasia, Bieganski typesevere X-linked mitochondrial encephalomyopathy
HGNC:8768UniProt:O95831
MT-ND2NADH-ubiquinone oxidoreductase chain 2Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:16996290). Essential for the catalytic activity and assembly of complex I (PubMed:16996290)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (4)
mitochondrial diseaseLeber hereditary optic neuropathymaternally-inherited Leigh syndromemitochondrial complex I deficiency
HGNC:7456UniProt:P03891
LIPT1Lipoyl amidotransferase LIPT1, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Lipoyl amidotransferase that catalyzes the transfer of lipoyl moieties from lipoyl-protein H of the glycine cleavage system (lipoyl-GCSH) to E2 subunits of the pyruvate dehydrogenase complex (PDCE2) (PubMed:29987032). Unable to catalyze the transfer of octanoyl from octanoyl-GCSH to PDCE2 (PubMed:29987032). In vitro, it is also able to catalyze the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes but this reaction may not

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Protein lipoylation
MECANISMO DE DOENÇA

Lipoyltransferase 1 deficiency

An autosomal recessive disorder due to a defect in lipoic acid metabolism, resulting in severe lactic acidosis and metabolic decompensation. Variable clinical manifestations include delayed psychomotor development, severe hypotonia, dystonia, loss of head control, coma, bradycardia, and pulmonary hypertension.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
14.5 TPM
Tireoide
11.8 TPM
Baço
11.8 TPM
Ovário
11.5 TPM
Próstata
10.8 TPM
OUTRAS DOENÇAS (1)
lipoyl transferase 1 deficiency
HGNC:29569UniProt:Q9Y234
UQCC2Ubiquinol-cytochrome c reductase complex assembly factor 2Candidate gene tested inTolerante
FUNÇÃO

Required for the assembly of the ubiquinol-cytochrome c reductase complex (mitochondrial respiratory chain complex III or cytochrome b-c1 complex). Plays a role in the modulation of respiratory chain activities such as oxygen consumption and ATP production and via its modulation of the respiratory chain activity can regulate skeletal muscle differentiation and insulin secretion by pancreatic beta-cells. Involved in cytochrome b translation and/or stability

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoidMitochondrionMitochondrion intermembrane spaceMitochondrion matrixMitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex III assembly
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 7

A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. MC3DN7 is characterized by severe intrauterine growth retardation, neonatal lactic acidosis and renal tubular dysfunction. Additional clinical features include a dysmorphic facial appearance, delayed psychomotor development, autistic features, aggressive behavior, and mild sensorineural hearing loss.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
76.4 TPM
Coração - Átrio
54.8 TPM
Pituitária
54.1 TPM
Fibroblastos
53.5 TPM
Coração - Ventrículo esquerdo
48.2 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency nuclear type 7mitochondrial complex III deficiency
HGNC:21237UniProt:Q9BRT2
UQCRC2Cytochrome b-c1 complex subunit 2, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex III assemblyMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 5

A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
245.0 TPM
Coração - Ventrículo esquerdo
227.3 TPM
Linfócitos
218.5 TPM
Coração - Átrio
189.2 TPM
Cólon transverso
159.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency nuclear type 5mitochondrial complex III deficiency
HGNC:12586UniProt:P22695
AMPD3AMP deaminase 3Candidate gene tested inTolerante
FUNÇÃO

AMP deaminase plays a critical role in energy metabolism

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Adenosine monophosphate deaminase deficiency erythrocyte type

A metabolic disorder due to lack of activity of the erythrocyte isoform of AMP deaminase. It is a clinically asymptomatic condition characterized by a 50% increase in steady-state levels of ATP in affected cells. Individuals with complete deficiency of erythrocyte AMP deaminase are healthy and have no hematologic disorders.

OUTRAS DOENÇAS (2)
obsolete erythrocyte AMP deaminase deficiencyadenosine monophosphate deaminase deficiency
HGNC:470UniProt:Q01432
PDHBPyruvate dehydrogenase E1 component subunit beta, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Together with PDHA1 forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex (PubMed:17474719, PubMed:19081061). The PDH complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3) (P

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (4)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYRMitochondrial protein degradation
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E1-beta deficiency

An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
122.9 TPM
Esôfago - Muscular
118.3 TPM
Fibroblastos
115.0 TPM
Coração - Ventrículo esquerdo
110.6 TPM
Artéria tibial
106.5 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E1-beta deficiency
HGNC:8808UniProt:P11177
PDP1Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6Candidate gene tested inRestrito
FUNÇÃO

Magnesium-independent polyisoprenoid diphosphatase that catalyzes the sequential dephosphorylation of presqualene, farnesyl, geranyl and geranylgeranyl diphosphates (PubMed:16464866, PubMed:19220020, PubMed:20110354). Functions in the innate immune response through the dephosphorylation of presqualene diphosphate which acts as a potent inhibitor of the signaling pathways contributing to polymorphonuclear neutrophils activation (PubMed:16464866, PubMed:23568778). May regulate the biosynthesis of

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus envelopeNucleus inner membrane

VIAS BIOLÓGICAS (1)
Regulation of pyruvate dehydrogenase (PDH) complex
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
51.5 TPM
Glândula adrenal
34.6 TPM
Testículo
29.8 TPM
Córtex cerebral
28.2 TPM
Fibroblastos
20.0 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase phosphatase deficiency
HGNC:9279UniProt:Q8IY26
DLATDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

The pyruvate dehydrogenase (PDH) complex, catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3); (Probable). Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
PDH complex synthesizes acetyl-CoA from PYRProtein lipoylationRegulation of pyruvate dehydrogenase (PDH) complex
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
38.4 TPM
Linfócitos
37.6 TPM
Coração - Ventrículo esquerdo
36.5 TPM
Fibroblastos
31.1 TPM
Coração - Átrio
26.7 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E2 deficiency
HGNC:2896UniProt:P10515
MT-ATP6ATP synthase F(0) complex subunit aCandidate gene tested inDesconhecido
FUNÇÃO

Subunit a, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the F(1

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Neuropathy, ataxia, and retinitis pigmentosa

A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy.

OUTRAS DOENÇAS (8)
mitochondrial diseasematernally-inherited Leigh syndromefamilial infantile bilateral striatal necrosismitochondrial proton-transporting ATP synthase complex deficiency
HGNC:7414UniProt:P00846
MT-TL1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (7)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeMERRF syndrome
HGNC:7490
MT-ND4NADH-ubiquinone oxidoreductase chain 4Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827, PubMed:8344246, PubMed:8644732). Essential for the catalytic activity and assembly of complex I (PubMed:15250827, PubMed:8344246, PubMed:8644732)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeLeber plus disease
HGNC:7459UniProt:P03905
QRSL1Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Allows the formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu-tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho-Glu-tRNA(Gln)

LOCALIZAÇÃO

Mitochondrion

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 40

An autosomal recessive mitochondrial disorder characterized by prenatal or infantile onset, fetal hydrops, severe hypertrophic cardiomyopathy, poor growth, sensorineural hearing loss, hepatic dysfunction, lactic acidosis, and decreased activities of mitochondrial respiratory complexes I, III, IV, and V. The disorder is lethal, with death occurring in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
17.2 TPM
Baço
12.2 TPM
Nervo tibial
10.9 TPM
Músculo esquelético
10.6 TPM
Fibroblastos
10.5 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation deficiency 40
HGNC:21020UniProt:Q9H0R6
MRPL3Large ribosomal subunit protein uL3mCandidate gene tested inTolerante
LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 9

A mitochondrial disease characterized by failure to thrive, poor feeding, hypertrophic cardiomyopathy, hepatomegaly, and psychomotor retardation. Death in infancy has been observed in some cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
147.1 TPM
Fibroblastos
142.8 TPM
Testículo
72.3 TPM
Tireoide
70.7 TPM
Ovário
69.2 TPM
OUTRAS DOENÇAS (1)
combined oxidative phosphorylation defect type 9
HGNC:10379UniProt:P09001
AARS2Alanine--tRNA ligase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:21549344). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine residues in target proteins, such as CGAS (PubMed:39322678). Acts as an inhibitor of cGAS/STING signaling by catalyzing lac

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 8

A mitochondrial disease characterized by a lethal infantile hypertrophic cardiomyopathy, generalized muscle dysfunction and some neurologic involvement. The liver is not affected.

OUTRAS DOENÇAS (4)
leukoencephalopathy, progressive, with ovarian failurecombined oxidative phosphorylation defect type 8leukoencephalopathy, diffuse hereditary, with spheroids 1obsolete ovarioleukodystrophy
HGNC:21022UniProt:Q5JTZ9
MT-ND1NADH-ubiquinone oxidoreductase chain 1Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:1959619). Essential for the catalytic activity and assembly of complex I (PubMed:1959619, PubMed:26929434)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Respiratory electron transportComplex I biogenesisMitochondrial translation terminationMitochondrial protein degradation
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (5)
mitochondrial diseaseMELAS syndromemitochondrial complex I deficiencymaternally-inherited Leigh syndrome
HGNC:7455UniProt:P03886
MT-TFCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
OUTRAS DOENÇAS (4)
mitochondrial diseaseMELAS syndromeGitelman-like kidney tubulopathy due to mitochondrial DNA mutationMERRF syndrome
HGNC:7481
POLG2DNA polymerase subunit gamma-2Candidate gene tested inTolerante
FUNÇÃO

Accessory subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Acts as an allosteric regulator of the holoenzyme activities. Enhances the polymerase activity and the processivity of POLG by increasing its interactions with the DNA template. Suppresses POLG exonucleolytic proofreading especially toward homopolymeric templates bearing mismatched termini. Binds to single-stranded DNA

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (2)
Strand-asynchronous mitochondrial DNA replicationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 4

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
30.1 TPM
Ovário
22.2 TPM
Linfócitos
19.3 TPM
Cervix Endocervix
18.3 TPM
Útero
16.6 TPM
OUTRAS DOENÇAS (4)
progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4mitochondrial DNA depletion syndrome 16 (hepatic type)mitochondrial dna depletion syndrome 16B (neuroophthalmic type)autosomal dominant progressive external ophthalmoplegia
HGNC:9180UniProt:Q9UHN1
MT-THCandidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Catecholamine biosynthesis
OUTRAS DOENÇAS (4)
mitochondrial diseaseMERRF syndromeMELAS syndromemitochondrial non-syndromic sensorineural hearing loss
HGNC:7487
MT-TS1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (6)
mitochondrial diseaseMERRF syndromepalmoplantar keratoderma-deafness syndromematernally-inherited progressive external ophthalmoplegia
HGNC:7497
COX5ACytochrome c oxidase subunit 5A, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (5)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assemblyMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 20

An autosomal recessive mitochondrial disorder with onset in early infancy. MC4DN20 is characterized by pulmonary arterial hypertension, poor feeding, failure to thrive, hypotonia, delayed development, increased serum lactate and metabolic acidosis. Death in infancy occurs due to cardiorespiratory failure. Patient tissues show variably decreased levels and activity of mitochondrial respiratory complex IV.

OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 20mitochondrial complex IV deficiency, nuclear-type
HGNC:2267UniProt:P20674
NDUFV1NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:28844695). Part of the peripheral arm of the enzyme, where the electrons from NADH are accepted by flavin mononucleotide (FMN) and then passed along a chain of iron-sulfur clusters by electron tunnelling to the final acceptor ubiquinone (PubMed:28844695). Contains FMN, which is the i

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 4

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN4 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
240.6 TPM
Coração - Ventrículo esquerdo
236.3 TPM
Linfócitos
234.0 TPM
Cerebelo
233.0 TPM
Músculo esquelético
222.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 4mitochondrial complex I deficiency
HGNC:7716UniProt:P49821
DGUOKDeoxyguanosine kinase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Phosphorylates deoxyguanosine and deoxyadenosine in the mitochondrial matrix, with the highest efficiency for deoxyguanosine (PubMed:11687801, PubMed:17073823, PubMed:23043144, PubMed:8692979, PubMed:8706825). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on DGUOK and TK2. Phosphorylates certain nucleoside analogs (By similarity). Widely used as target of antiviral and chemotherapeutic agents

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Purine salvage
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 3

A disorder due to mitochondrial dysfunction characterized by onset in infancy of progressive liver failure, hypoglycemia, increased lactate in body fluids, and neurologic abnormalities including hypotonia, encephalopathy, peripheral neuropathy. Affected tissues show both decreased activity of the mtDNA-encoded respiratory chain complexes and mtDNA depletion.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
78.1 TPM
Pituitária
72.5 TPM
Ovário
63.9 TPM
Aorta
61.4 TPM
Testículo
61.4 TPM
OUTRAS DOENÇAS (3)
mitochondrial DNA depletion syndrome 3 (hepatocerebral type)portal hypertension, noncirrhotic, 1progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4
HGNC:2858UniProt:Q16854
GUK1Guanylate kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the phosphorylation of GMP to GDP. Essential enzyme for recycling GMP and indirectly, cyclic GMP (cGMP) (PubMed:31201273). Involved in the cGMP metabolism in photoreceptors (By similarity). It may also have a role in the survival and growth progression of some tumors (PubMed:31201273). In addition to its physiological role, GUK1 is essential for converting prodrugs used for the treatment of cancers and viral infections into their pharmacologically active metabolites, most notably acycl

LOCALIZAÇÃO

Photoreceptor inner segmentCytoplasm, cytosolMitochondrion

VIAS BIOLÓGICAS (2)
Interconversion of nucleotide di- and triphosphatesAzathioprine ADME
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 21

An autosomal recessive mitochondrial disorder characterized by ptosis, ophthalmoparesis, myopathic proximal limb weakness, variable hepatopathy, and altered T-lymphocyte profiles. Multiple mtDNA deletions and depletion are detected in muscle, as well as mitochondrial respiratory chain deficiencies.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
190.6 TPM
Aorta
151.5 TPM
Nervo tibial
150.8 TPM
Skin Not Sun Exposed Suprapubic
143.3 TPM
Brain Frontal Cortex BA9
140.6 TPM
OUTRAS DOENÇAS (1)
mitochondrial dna depletion syndrome 21
HGNC:HGNC:4693UniProt:Q16774
TYMPThymidine phosphorylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Pyrimidine salvagePyrimidine catabolism
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 1, MNGIE type

A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
330.6 TPM
Pulmão
260.6 TPM
Baço
215.3 TPM
Tecido adiposo
140.0 TPM
Adipose Visceral Omentum
116.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 1mitochondrial neurogastrointestinal encephalomyopathy
HGNC:3148UniProt:P19971
PDHXPyruvate dehydrogenase protein X component, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for anchoring dihydrolipoamide dehydrogenase (E3) to the dihydrolipoamide transacetylase (E2) core of the pyruvate dehydrogenase complexes of eukaryotes. This specific binding is essential for a functional PDH complex

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYR
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E3-binding protein deficiency

A metabolic disorder characterized by decreased activity of the pyruvate dehydrogenase complex without observable reduction in the activities of enzymes E1, E2, or E3. Clinical features include hypotonia and psychomotor retardation.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
53.1 TPM
Coração - Ventrículo esquerdo
36.7 TPM
Testículo
34.8 TPM
Linfócitos
30.1 TPM
Cérebro - Hemisfério cerebelar
28.5 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3-binding protein deficiency
HGNC:21350UniProt:O00330
DLDDihydrolipoyl dehydrogenase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lipoamide dehydrogenase is a component of the glycine cleavage system as well as an E3 component of three alpha-ketoacid dehydrogenase complexes (pyruvate-, alpha-ketoglutarate-, and branched-chain amino acid-dehydrogenase complex) (PubMed:15712224, PubMed:16442803, PubMed:16770810, PubMed:17404228, PubMed:20160912, PubMed:20385101). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion (PubMed:29211711). A fraction of the 2-oxoglutarate dehydrogenase complex also locali

LOCALIZAÇÃO

Mitochondrion matrixNucleusCell projection, cilium, flagellumCytoplasmic vesicle, secretory vesicle, acrosome

VIAS BIOLÓGICAS (10)
BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIVBranched-chain amino acid catabolismBranched-chain ketoacid dehydrogenase kinase deficiencyH139Hfs13* PPM1K causes a mild variant of MSUDSignaling by Retinoic Acid
MECANISMO DE DOENÇA

Dihydrolipoamide dehydrogenase deficiency

An autosomal recessive metabolic disorder characterized biochemically by a combined deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate dehydrogenase complex (KGDC). Clinically, affected individuals have lactic acidosis and neurologic deterioration due to sensitivity of the central nervous system to defects in oxidative metabolism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.2 TPM
Coração - Ventrículo esquerdo
70.7 TPM
Músculo esquelético
69.5 TPM
Esôfago - Muscular
69.5 TPM
Glândula adrenal
69.1 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E3 deficiency
HGNC:2898UniProt:P09622
PDHA1Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrialDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Together with PDHB forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex (PubMed:17474719, PubMed:19081061). The PDH complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (PubMed:19081061, PubMed:7782287). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (4)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYRMitochondrial protein degradation
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E1-alpha deficiency

An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
136.8 TPM
Coração - Átrio
101.8 TPM
Músculo esquelético
97.1 TPM
Rim - Medula
76.9 TPM
Linfócitos
70.4 TPM
OUTRAS DOENÇAS (2)
pyruvate dehydrogenase E1-alpha deficiencypyruvate dehydrogenase deficiency
HGNC:8806UniProt:P08559
PMPCBMitochondrial-processing peptidase subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the essential mitochondrial processing protease (MPP), which cleaves the mitochondrial sequence off newly imported precursors proteins (Probable) (PubMed:29576218). Preferentially, cleaves after an arginine at position P2 (By similarity). Required for PINK1 turnover by coupling PINK1 mitochondrial import and cleavage, which results in subsequent PINK1 proteolysis (PubMed:22354088)

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Mitochondrial protein importProcessing of SMDT1
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 6

An autosomal recessive, neurodegenerative disorder characterized by basal ganglia lesions, cerebellar atrophy, and neurologic regression in the first year of life. Common features include truncal hypotonia, lack of independent ambulation, poor speech, intellectual disability, and motor abnormalities, such as ataxia, dystonia, and spasticity.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
85.0 TPM
Ovário
68.1 TPM
Cervix Endocervix
66.3 TPM
Útero
65.9 TPM
Artéria tibial
64.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 6
HGNC:9119UniProt:O75439
ISCA2Iron-sulfur cluster assembly 2 homolog, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. May be involved in the binding of an intermediate of Fe/S cluster assembly

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (2)
Maturation of TCA enzymes and regulation of TCA cycleMitochondrial iron-sulfur cluster biogenesis
MECANISMO DE DOENÇA

Multiple mitochondrial dysfunctions syndrome 4

A severe disorder of systemic energy metabolism, resulting in weakness, respiratory failure, lack of neurologic development, lactic acidosis, hyperglycinemia and early death.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
21.5 TPM
Linfócitos
20.0 TPM
Glândula adrenal
18.8 TPM
Fibroblastos
18.2 TPM
Testículo
17.7 TPM
OUTRAS DOENÇAS (1)
multiple mitochondrial dysfunctions syndrome 4
HGNC:19857UniProt:Q86U28
HADHBTrifunctional enzyme subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial trifunctional enzyme catalyzes the last three of the four reactions of the mitochondrial beta-oxidation pathway (PubMed:29915090, PubMed:30850536, PubMed:8135828). The mitochondrial beta-oxidation pathway is the major energy-producing process in tissues and is performed through four consecutive reactions breaking down fatty acids into acetyl-CoA (PubMed:29915090). Among the enzymes involved in this pathway, the trifunctional enzyme exhibits specificity for long-chain fatty acids (P

LOCALIZAÇÃO

MitochondrionMitochondrion inner membraneMitochondrion outer membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (8)
Acyl chain remodeling of CLBeta oxidation of hexanoyl-CoA to butanoyl-CoABeta oxidation of octanoyl-CoA to hexanoyl-CoABeta oxidation of decanoyl-CoA to octanoyl-CoA-CoABeta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
MECANISMO DE DOENÇA

Mitochondrial trifunctional protein deficiency 2

An autosomal recessive metabolic disorder of long-chain fatty acid oxidation, biochemically characterized by loss of all enzyme activities of the mitochondrial trifunctional protein complex. The disease phenotype ranges from a fatal form characterized by early-onset cardiomyopathy, cardiac failure and early death to less severe, late-onset forms with myopathy, recurrent rhabdomyolysis, and sensorimotor axonal neuropathy as key features.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
375.3 TPM
Coração - Ventrículo esquerdo
307.5 TPM
Coração - Átrio
223.3 TPM
Glândula adrenal
186.5 TPM
Esôfago - Muscular
129.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial trifunctional protein deficiency 2mitochondrial trifunctional protein deficiency
HGNC:4803UniProt:P55084
MPC1Mitochondrial pyruvate carrier 1Disease-causing germline mutation(s) inModerado
FUNÇÃO

Mediates the uptake of pyruvate into mitochondria to maintain the balance between glycolysis and oxidative phosphorylation (PubMed:22628558, PubMed:26253029, PubMed:27317664, PubMed:40044865, PubMed:40101766). Plays an essential role in cellular metabolism (PubMed:40044865, PubMed:40101766)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Pyruvate metabolism
MECANISMO DE DOENÇA

Mitochondrial pyruvate carrier deficiency

An autosomal recessive metabolic disorder characterized by severely delayed psychomotor development, mild dysmorphic features, hepatomegaly, marked metabolic acidosis, hyperlactacidemia with normal lactate/pyruvate, and encephalopathy. Some patients have epilepsy and peripheral neuropathy.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
168.8 TPM
Brain Spinal cord cervical c-1
164.5 TPM
Coração - Átrio
144.6 TPM
Rim - Medula
132.4 TPM
Fígado
131.9 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
mitochondrial pyruvate carrier deficiency
HGNC:21606UniProt:Q9Y5U8
ATP5F1AATP synthase F(1) complex subunit alpha, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the

LOCALIZAÇÃO

MitochondrionMitochondrion inner membraneCell membrane

VIAS BIOLÓGICAS (3)
Formation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 22

A mitochondrial disorder characterized by intrauterine growth retardation, microcephaly, hypotonia, pulmonary hypertension, failure to thrive, encephalopathy, and heart failure.

OUTRAS DOENÇAS (4)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 4Amitochondrial complex V (ATP synthase) deficiency, nuclear type 4Bcombined oxidative phosphorylation deficiency 22mitochondrial proton-transporting ATP synthase complex deficiency
HGNC:823UniProt:P25705
TMEM70Transmembrane protein 70, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Scaffold protein that participates in the c-ring assembly of mitochondrial ATP synthase (F(1)F(0) ATP synthase or complex V) by facilitating the membrane insertion and oligomer formation of the subunit c/ATP5MC1 through its interaction (PubMed:31652072, PubMed:32275929, PubMed:33359711, PubMed:33753518). Therefore, participates in the early stage of mitochondrial ATP synthase biogenesis and also protects subunit c/ATP5MC1 against intramitochondrial proteolysis (PubMed:18953340, PubMed:20937241,

LOCALIZAÇÃO

Mitochondrion inner membrane

MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, nuclear type 2

A mitochondrial disorder with heterogeneous clinical manifestations including dysmorphic features, psychomotor retardation, hypotonia, growth retardation, cardiomyopathy, enlarged liver, hypoplastic kidneys and elevated lactate levels in urine, plasma and cerebrospinal fluid.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
54.5 TPM
Linfócitos
32.1 TPM
Glândula adrenal
29.1 TPM
Brain Frontal Cortex BA9
28.8 TPM
Adipose Visceral Omentum
26.8 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 2
HGNC:26050UniProt:Q9BUB7
LRPPRCLeucine-rich PPR motif-containing protein, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in RNA metabolism in both nuclei and mitochondria. In the nucleus binds to HNRPA1-associated poly(A) mRNAs and is part of nmRNP complexes at late stages of mRNA maturation which are possibly associated with nuclear mRNA export. Positively modulates nuclear export of mRNAs containing the EIF4E sensitivity element (4ESE) by binding simultaneously to both EIF4E and the 4ESE and acting as a platform for assembly for the RNA export complex (PubMed:19262567, PubMed:28325843). Also bind

LOCALIZAÇÃO

MitochondrionNucleusNucleus, nucleoplasmNucleus inner membraneNucleus outer membrane

VIAS BIOLÓGICAS (2)
Mitochondrial mRNA modificationMitochondrial RNA degradation
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 5

An autosomal recessive, severe mitochondrial disease with multisystemic manifestations and early onset. Clinical features include delayed psychomotor development, impaired intellectual development with speech delay, mild dysmorphic facial features, hypotonia, ataxia, and seizures. Brain imaging shows bilaterally symmetrical necrotic lesions in subcortical brain regions. Mortality is high, due to episodes of severe metabolic acidosis and coma.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
113.8 TPM
Cérebro - Hemisfério cerebelar
71.9 TPM
Fibroblastos
69.4 TPM
Músculo esquelético
59.7 TPM
Cerebelo
56.5 TPM
OUTRAS DOENÇAS (1)
congenital lactic acidosis, Saguenay-Lac-Saint-Jean type
HGNC:15714UniProt:P42704
COX20Cytochrome c oxidase assembly protein COX20, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Essential for the assembly of the mitochondrial respiratory chain complex IV (CIV), also known as cytochrome c oxidase (PubMed:23125284). Acts as a chaperone in the early steps of cytochrome c oxidase subunit II (MT-CO2/COX2) maturation, stabilizing the newly synthesized protein and presenting it to metallochaperones SCO1/2 which in turn facilitates the incorporation of the mature MT-CO2/COX2 into the assembling CIV holoenzyme (PubMed:24403053)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 11

An autosomal recessive mitochondrial disorder with onset in childhood or adolescence. MC4DN11 is characterized by walking difficulties, cerebellar ataxia, dystonia, choreoathetotic movements and dysarthria. Additional features may include sensory axonal neuropathy, cerebellar atrophy, and mild speech delay. Cognitive function is normal. Serum lactate levels are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 11mitochondrial complex IV deficiency, nuclear-type
HGNC:26970UniProt:Q5RI15
NDUFS3NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:14729820, PubMed:30140060). Essential for the catalytic activity and assembly of complex I (PubMed:14729820, PubMed:24028823, PubMed:30140060)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 8

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN8 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
78.6 TPM
Cérebro - Hemisfério cerebelar
77.7 TPM
Brain Caudate basal ganglia
72.3 TPM
Brain Putamen basal ganglia
68.8 TPM
Brain Frontal Cortex BA9
68.7 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 8mitochondrial complex I deficiency
HGNC:7710UniProt:O75489
TMEM126BComplex I assembly factor TMEM126B, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

As part of the MCIA complex, involved in the assembly of the mitochondrial complex I (PubMed:27374773, PubMed:27374774, PubMed:32320651). Participates in constructing the membrane arm of complex I (PubMed:24191001)

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 29

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN29 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
44.8 TPM
Útero
40.8 TPM
Nervo tibial
40.0 TPM
Cervix Endocervix
38.4 TPM
Fibroblastos
38.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 29mitochondrial complex I deficiency
HGNC:30883UniProt:Q8IUX1
MTFMTMethionyl-tRNA formyltransferase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Methionyl-tRNA formyltransferase that formylates methionyl-tRNA in mitochondria and is crucial for translation initiation

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial translation initiation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 15

An autosomal recessive, mitochondrial, neurologic disorder characterized by features of Leigh syndrome and combined oxidative phosphorylation deficiency. Clinical features include mild global developmental delay, white matter abnormalities, ataxia, incoordination, speech and reading difficulties, T2-weighted hyperintensities in the basal ganglia, corpus callosum, and brainstem.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
12.8 TPM
Fallopian Tube
12.8 TPM
Cervix Endocervix
12.1 TPM
Cervix Ectocervix
11.7 TPM
Cérebro - Hemisfério cerebelar
11.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 27combined oxidative phosphorylation defect type 15
HGNC:29666UniProt:Q96DP5
NDUFA1NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1Disease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 12

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
754.6 TPM
Coração - Átrio
614.2 TPM
Rim - Medula
479.1 TPM
Músculo esquelético
469.9 TPM
Linfócitos
453.6 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 12mitochondrial complex I deficiency
HGNC:7683UniProt:O15239
TRMUMitochondrial tRNA-specific 2-thiouridylase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the 2-thiolation of uridine at the wobble position (U34) of mitochondrial tRNA(Lys), tRNA(Glu) and tRNA(Gln). Required for the formation of 5-taurinomethyl-2-thiouridine (tm5s2U) of mitochondrial tRNA(Lys), tRNA(Glu), and tRNA(Gln) at the wobble position. ATP is required to activate the C2 atom of the wobble base

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
tRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Deafness, aminoglycoside-induced

A form of sensorineural deafness characterized by moderate-to-profound hearing loss and mitochondrial inheritance. It is induced by exposure to aminoglycosides.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
22.9 TPM
Cérebro - Hemisfério cerebelar
21.9 TPM
Linfócitos
20.7 TPM
Cervix Endocervix
19.9 TPM
Pituitária
19.9 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (4)
acute infantile liver failure due to synthesis defect of mtDNA-encoded proteinsmitochondrial myopathy with reversible cytochrome C oxidase deficiencymitochondrial non-syndromic sensorineural hearing lossdeafness, aminoglycoside-induced
HGNC:25481UniProt:O75648
LARS2Leucine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of leucine to its cognate tRNA

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Perrault syndrome 4

An autosomal recessive, sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
22.1 TPM
Fibroblastos
20.3 TPM
Córtex cerebral
13.1 TPM
Brain Frontal Cortex BA9
13.1 TPM
Brain Nucleus accumbens basal ganglia
12.9 TPM
OUTRAS DOENÇAS (4)
Perrault syndrome 4hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndromePerrault syndrome 2Perrault syndrome 1
HGNC:17095UniProt:Q15031
HARS2D-aminoacyl-tRNA deacylase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Possible ATPase (PubMed:15653697) involved in DNA replication, may facilitate loading of CDC45 onto pre-replication complexes (PubMed:20065034) An aminoacyl-tRNA editing enzyme that deacylates mischarged D-aminoacyl-tRNAs. Also deacylates mischarged glycyl-tRNA(Ala), protecting cells against glycine mischarging by AlaRS. Acts via tRNA-based rather than protein-based catalysis; rejects L-amino acids rather than detecting D-amino acids in the active site. By recycling D-aminoacyl-tRNA to D-amino a

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
60.5 TPM
Cerebelo
58.0 TPM
Útero
55.0 TPM
Nervo tibial
52.6 TPM
Fallopian Tube
49.9 TPM
OUTRAS DOENÇAS (2)
Perrault syndrome 2Perrault syndrome 1
HGNC:4817UniProt:Q8TEA8
FDXRNADPH:adrenodoxin oxidoreductase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver (By similarity). Also acts as a ferredoxin--NADP(+) reductase essential for coenzyme Q biosynthesis: together with FDX2, transfers the electrons required for the hydroxylation reaction performed by C

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Electron transport from NADPH to FerredoxinEndogenous sterolsPregnenolone biosynthesisDefective CYP11A1 causes AICSR
MECANISMO DE DOENÇA

Auditory neuropathy and optic atrophy

An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
302.8 TPM
Testículo
77.8 TPM
Baço
43.0 TPM
Linfócitos
37.8 TPM
Ovário
37.6 TPM
OUTRAS DOENÇAS (3)
multiple mitochondrial dysfunctions syndrome 9bauditory neuropathy-optic atrophy syndromeoptic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome
HGNC:3642UniProt:P22570
POLGDNA polymerase subunit gamma-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
ATP5F1DATP synthase F(1) complex subunit delta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Subunit delta, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable) (PubMed:37244256). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk r

LOCALIZAÇÃO

MitochondrionMitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Formation of ATP by chemiosmotic couplingCristae formation
MECANISMO DE DOENÇA

Mitochondrial complex V deficiency, nuclear type 5

A mitochondrial disorder characterized by childhood onset of episodic metabolic decompensation featuring lactic acidosis and hyperammonemia accompanied by ketoacidosis or hypoglycemia. Chronic manifestations include developmental delay, easy fatiguability, and 3-methylglutaconic aciduria. The transmission pattern of MC5DN5 is consistent with autosomal recessive inheritance.

OUTRAS DOENÇAS (2)
mitochondrial complex V (ATP synthase) deficiency, nuclear type 5mitochondrial proton-transporting ATP synthase complex deficiency
HGNC:837UniProt:P30049
SCO2Cytochrome c oxidase assembly factor SCO2Disease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Copper metallochaperone essential for the synthesis and maturation of cytochrome c oxidase subunit II (MT-CO2/COX2); together with SCO1, facilitates the incorporation of copper into the Cu(A) site of MT-CO2/COX2 (PubMed:15229189, PubMed:17189203, PubMed:19336478, PubMed:35750769). Could also act as a thiol-disulfide oxidoreductase to regulate the redox state of the cysteines in SCO1 during maturation of MT-CO2/COX2 (PubMed:19336478)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
TP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 2

An autosomal recessive, severe mitochondrial disorder characterized by hypotonia, global developmental delay, hypertrophic cardiomyopathy, lactic acidosis, gliosis, and neuronal loss in basal ganglia, brainstem and spinal cord. Serum lactate is increased, and laboratory studies show decreased mitochondrial complex IV protein and activity levels in various tissues, including heart and skeletal muscle. Most patients die in infancy of cardiorespiratory failure.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
32.4 TPM
Pulmão
32.3 TPM
Fibroblastos
29.5 TPM
Esôfago - Mucosa
28.2 TPM
Fallopian Tube
28.1 TPM
OUTRAS DOENÇAS (5)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1myopia 6autosomal recessive axonal charcot-marie-tooth disease due to copper metabolism defectfatal infantile encephalocardiomyopathy
HGNC:10604UniProt:O43819
COA6Cytochrome c oxidase assembly factor 6 homologDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the maturation of the mitochondrial respiratory chain complex IV subunit MT-CO2/COX2. Thereby, may regulate early steps of complex IV assembly. Mitochondrial respiratory chain complex IV or cytochrome c oxidase is the component of the respiratory chain that catalyzes the transfer of electrons from intermembrane space cytochrome c to molecular oxygen in the matrix and as a consequence contributes to the proton gradient involved in mitochondrial ATP synthesis. May also be required for

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 13

An autosomal recessive, infantile disorder with a fatal course in the first weeks of life, characterized by hypertrophic cardiomyopathy, left ventricular non-compaction, lactic acidosis, metabolic hypotonia, and mitochondrial complex IV deficiency.

OUTRAS DOENÇAS (2)
cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4fatal infantile encephalocardiomyopathy
HGNC:18025UniProt:Q5JTJ3
UQCRQCytochrome b-c1 complex subunit 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex III assemblyMitochondrial protein degradation
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 4

A disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. Clinical features include mitochondrial encephalopathy, psychomotor retardation, ataxia, severe failure to thrive, liver dysfunction, renal tubulopathy, muscle weakness and exercise intolerance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
368.3 TPM
Músculo esquelético
306.8 TPM
Fígado
286.8 TPM
Coração - Átrio
284.2 TPM
Fibroblastos
237.5 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency nuclear type 4mitochondrial complex III deficiency
HGNC:29594UniProt:O14949
UQCRFS1Cytochrome b-c1 complex subunit Rieske, mitochondrialDisease-causing germline mutation(s) inModerado
FUNÇÃO

Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation (PubMed:31883641). The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succi

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex III assembly
MECANISMO DE DOENÇA

Mitochondrial complex III deficiency, nuclear type 10

A form of mitochondrial complex III deficiency, a disorder of the mitochondrial respiratory chain resulting in a highly variable phenotype depending on which tissues are affected. MC3DN10 is an autosomal recessive form characterized by fetal bradycardia, poor feeding, hypotonia, hypertrophic cardiomyopathy, alopecia totalis, low mitochondrial complex III activity and lactic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
133.8 TPM
Coração - Ventrículo esquerdo
102.0 TPM
Coração - Átrio
86.6 TPM
Rim - Medula
78.3 TPM
Linfócitos
76.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex III deficiency, nuclear type 10mitochondrial complex III deficiency
HGNC:12587UniProt:P47985
NDUFS7NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:17275378). Essential for the catalytic activity of complex I (PubMed:17275378)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 3

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN3 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
88.0 TPM
Cérebro - Hemisfério cerebelar
84.6 TPM
Cerebelo
84.0 TPM
Testículo
68.2 TPM
Coração - Ventrículo esquerdo
64.3 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 3mitochondrial complex I deficiency
HGNC:7714UniProt:O75251
NDUFA10NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 22

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN22 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
95.5 TPM
Cerebelo
92.4 TPM
Nervo tibial
52.4 TPM
Coração - Ventrículo esquerdo
50.1 TPM
Linfócitos
47.7 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex I deficiency, nuclear type 22
HGNC:HGNC:7684UniProt:O95299
NUBPLIron-sulfur cluster transfer protein NUBPLDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Iron-sulfur cluster transfer protein involved in the assembly of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) (PubMed:19752196). May deliver one or more Fe-S clusters to complex I subunits (PubMed:19752196)

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 21

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN21 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.0 TPM
Ovário
7.6 TPM
Nervo tibial
7.4 TPM
Linfócitos
7.3 TPM
Tecido adiposo
7.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 21mitochondrial complex I deficiency
HGNC:20278UniProt:Q8TB37
NDUFS8NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:22499348). Essential for the catalytic activity and assembly of complex I (PubMed:22499348)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 2

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN2 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
151.7 TPM
Coração - Ventrículo esquerdo
104.0 TPM
Coração - Átrio
101.5 TPM
Músculo esquelético
94.8 TPM
Pituitária
93.8 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex I deficiency, nuclear type 2mitochondrial complex I deficiency
HGNC:7715UniProt:O00217
TWNKTwinkle mtDNA helicaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial helicase involved in mtDNA replication and repair (PubMed:12975372, PubMed:15167897, PubMed:17324440, PubMed:18039713, PubMed:18971204, PubMed:25824949, PubMed:26887820, PubMed:27226550). Might have a role in mtDNA repair (PubMed:27226550). Has DNA strand separation activity needed to form a processive replication fork for leading strand synthesis which is catalyzed by the formation of a replisome complex with POLG and mtSDB (PubMed:12975372, PubMed:15167897, PubMed:18039713, PubMe

LOCALIZAÇÃO

Mitochondrion matrix, mitochondrion nucleoidMitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Strand-asynchronous mitochondrial DNA replicationMitochondrial protein degradationTranscriptional activation of mitochondrial biogenesis
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 3

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.9 TPM
Testículo
20.3 TPM
Fibroblastos
14.6 TPM
Ovário
10.6 TPM
Útero
10.3 TPM
OUTRAS DOENÇAS (8)
mitochondrial DNA depletion syndrome 7 (hepatocerebral type)Perrault syndrome 5progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3autosomal dominant progressive external ophthalmoplegia
HGNC:1160UniProt:Q96RR1
SUCLA2Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

ATP-specific succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to the synthesis of ATP and thus represents the only step of substrate-level phosphorylation in the TCA (PubMed:15877282, PubMed:34492704, PubMed:40108300). The beta subunit provides nucleotide specificity of the enzyme and binds the substrate succinate, while the binding sites for coenzyme A and phosphate are found in the alpha subunit (By similarity). Also able to act as an AT

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Citric acid cycle (TCA cycle)
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 5

A disorder due to mitochondrial dysfunction. It is characterized by infantile onset of hypotonia, neurologic deterioration, a hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, variable renal tubular dysfunction, and mild methylmalonic aciduria in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
60.1 TPM
Cérebro - Hemisfério cerebelar
57.5 TPM
Brain Frontal Cortex BA9
44.4 TPM
Cerebelo
44.3 TPM
Artéria tibial
37.9 TPM
OUTRAS DOENÇAS (1)
mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
HGNC:11448UniProt:Q9P2R7
RARS2Probable arginine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the attachment of arginine to tRNA(Arg) in a two-step reaction: arginine is first activated by ATP to form Arg-AMP and then transferred to the acceptor end of tRNA(Arg)

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 6

A disorder characterized by an abnormally small cerebellum and brainstem, infantile encephalopathy, generalized hypotonia, lethargy and poor feeding. Recurrent apnea, intractable seizures occur early in the course of this condition.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
47.3 TPM
Glândula adrenal
46.1 TPM
Útero
43.0 TPM
Cervix Ectocervix
42.3 TPM
Cervix Endocervix
42.1 TPM
OUTRAS DOENÇAS (1)
pontocerebellar hypoplasia type 6
HGNC:21406UniProt:Q5T160
ERAL1GTPase Era, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable GTPase that plays a role in the mitochondrial ribosomal small subunit assembly. Specifically binds the 12S mitochondrial rRNA (12S mt-rRNA) to a 33 nucleotide section delineating the 3' terminal stem-loop region. May act as a chaperone that protects the 12S mt-rRNA on the 28S mitoribosomal subunit during ribosomal small subunit assembly

LOCALIZAÇÃO

Mitochondrion matrixMitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationMitochondrial ribosome-associated quality controlMitochondrial translation initiationMitochondrial translation elongation
MECANISMO DE DOENÇA

Perrault syndrome 6

A form of Perrault syndrome, a sex-influenced disorder characterized by sensorineural deafness in both males and females, and ovarian dysgenesis in females. Affected females have primary amenorrhea, streak gonads, and infertility, whereas affected males show normal pubertal development and are fertile. PRLTS6 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
88.6 TPM
Cerebelo
84.5 TPM
Linfócitos
71.5 TPM
Fibroblastos
68.2 TPM
Útero
63.8 TPM
OUTRAS DOENÇAS (3)
Perrault syndrome 6Perrault syndrome 1Perrault syndrome 2
HGNC:3424UniProt:O75616
AFG3L2Mitochondrial inner membrane m-AAA protease component AFG3L2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic component of the m-AAA protease, a protease that plays a key role in proteostasis of inner mitochondrial membrane proteins, and which is essential for axonal and neuron development (PubMed:19748354, PubMed:28396416, PubMed:29932645, PubMed:30683687, PubMed:31327635, PubMed:37917749, PubMed:38157846). AFG3L2 possesses both ATPase and protease activities: the ATPase activity is required to unfold substrates, threading them into the internal proteolytic cavity for hydrolysis into small pe

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Processing of SMDT1Mitochondrial protein degradation
MECANISMO DE DOENÇA

Spinocerebellar ataxia 28

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA28 is an autosomal dominant cerebellar ataxia (ADCA) with a slow progressive course and no evidence of sensory involvement or cognitive impairment.

OUTRAS DOENÇAS (3)
optic atrophy 12spinocerebellar ataxia type 28spastic ataxia 5
HGNC:315UniProt:Q9Y4W6
COX6B1Cytochrome c oxidase subunit 6B1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation. The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase (complex IV, CIV), that cooperate to transfer electrons derived from NADH and succinate to molecular oxygen, creating an electrochemical gradient over t

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Cytoprotection by HMOX1Respiratory electron transportTP53 Regulates Metabolic GenesComplex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 7

An autosomal recessive mitochondrial disorder characterized by encephalomyopathy resulting in variable clinical manifestations. Features include muscle weakness, gait disturbances, neurodegeneration, cognitive decline, metabolic acidosis, feeding difficulties, poor overall growth, cortical visual impairment, and hypertrophic cardiomyopathy. Serum lactate levels are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV.

OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 7mitochondrial complex IV deficiency, nuclear-type
HGNC:2280UniProt:P14854
COX10Protoheme IX farnesyltransferase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts protoheme IX and farnesyl diphosphate to heme O

LOCALIZAÇÃO

Mitochondrion membrane

VIAS BIOLÓGICAS (1)
Heme biosynthesis
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 3

An autosomal recessive mitochondrial disorder characterized by cytochrome c oxidase deficiency. Clinical features include muscle weakness, hypotonia, ataxia, ptosis, metabolic acidosis, poor feeding, delayed motor development, anemia, sensorineural hearing loss, and cardiomyopathy.

VIAS REACTOME (1)
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 3mitochondrial complex IV deficiency, nuclear-type
HGNC:2260UniProt:Q12887
SURF1Surfeit locus protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex, that regulates cytochrome c oxidase assembly

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Complex IV assembly
MECANISMO DE DOENÇA

Mitochondrial complex IV deficiency, nuclear type 1

An autosomal recessive disorder of the mitochondrial respiratory chain characterized by early-onset, rapidly progressive encephalopathy, neurodegeneration, and loss of motor and cognitive skills. Affected individuals show hypotonia, failure to thrive, loss of the ability to sit or walk, poor communication, poor eye contact, oculomotor abnormalities, as well as deafness, ataxia, tremor, and brisk tendon reflexes. Brain imaging shows bilateral symmetric lesions in the basal ganglia. Lactate levels in serum and cerebrospinal fluid are increased. Patient tissues show decreased levels and activity of mitochondrial respiratory complex IV. Death in childhood may occur, often due to central respiratory failure.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
67.2 TPM
Artéria tibial
65.0 TPM
Aorta
63.9 TPM
Cólon sigmoide
62.4 TPM
Esôfago - Junção
60.0 TPM
OUTRAS DOENÇAS (2)
mitochondrial complex IV deficiency, nuclear type 1Charcot-Marie-Tooth disease type 4K
HGNC:11474UniProt:Q15526
SDHASuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:10746566, PubMed:24781757). SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Maturation of TCA enzymes and regulation of TCA cycle
MECANISMO DE DOENÇA

Mitochondrial complex II deficiency, nuclear type 1

A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. MC2DN1 inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
302.0 TPM
Músculo esquelético
237.6 TPM
Coração - Átrio
206.8 TPM
Glândula adrenal
172.2 TPM
Linfócitos
168.3 TPM
OUTRAS DOENÇAS (9)
mitochondrial complex II deficiency, nuclear type 1pheochromocytoma/paraganglioma syndrome 5neurodegeneration with ataxia and late-onset optic atrophydilated cardiomyopathy 1GG
HGNC:10680UniProt:P31040
NDUFS2NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:22036843, PubMed:28031252, PubMed:30922174). Essential for the catalytic activity of complex I (PubMed:22036843, PubMed:30922174). Essential for the assembly of complex I (By similarity). Redox-sensitive, critical component of the oxygen-sensing pathway in the pulmonary vasculature w

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 6

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN6 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
154.5 TPM
Ovário
130.0 TPM
Cérebro - Hemisfério cerebelar
124.7 TPM
Coração - Ventrículo esquerdo
120.8 TPM
Cerebelo
120.6 TPM
OUTRAS DOENÇAS (4)
mitochondrial complex I deficiency, nuclear type 6Leber-like hereditary optic neuropathy, autosomal recessive 2mitochondrial complex I deficiencyLeber hereditary optic neuropathy
HGNC:7708UniProt:O75306
NDUFA8NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis (PubMed:27626371, PubMed:32385911, PubMed:33153867). Complex I functions in the transfer of electrons from NADH to the respiratory chain (PubMed:27626371). The immediate electron acceptor for the enzyme is believed to be ubiquinone (PubMed:27626371)

LOCALIZAÇÃO

Mitochondrion inner membraneMitochondrion intermembrane spaceMitochondrion

VIAS BIOLÓGICAS (2)
Respiratory electron transportComplex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 37

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN37 features include developmental delay, cerebral atrophy, epilepsy, growth retardation, congenital myopathy with disproportion of fibers, and severely decreased activity of complex I. MC1DN37 transmission pattern is consistent with autosomal recessive inheritance.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
220.3 TPM
Coração - Átrio
208.0 TPM
Testículo
204.3 TPM
Brain Frontal Cortex BA9
172.0 TPM
Cólon sigmoide
162.4 TPM
OUTRAS DOENÇAS (1)
mitochondrial complex I deficiency, nuclear type 37
HGNC:HGNC:7692UniProt:P51970
NDUFAF6NADH dehydrogenase (ubiquinone) complex I, assembly factor 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the assembly of mitochondrial NADH:ubiquinone oxidoreductase complex (complex I) at early stages. May play a role in the biogenesis of complex I subunit MT-ND1

LOCALIZAÇÃO

Mitochondrion inner membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Complex I biogenesis
MECANISMO DE DOENÇA

Mitochondrial complex I deficiency, nuclear type 17

A form of mitochondrial complex I deficiency, the most common biochemical signature of mitochondrial disorders, a group of highly heterogeneous conditions characterized by defective oxidative phosphorylation, which collectively affects 1 in 5-10000 live births. Clinical disorders have variable severity, ranging from lethal neonatal disease to adult-onset neurodegenerative disorders. Phenotypes include macrocephaly with progressive leukodystrophy, non-specific encephalopathy, cardiomyopathy, myopathy, liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some forms of Parkinson disease. MC1DN17 transmission pattern is consistent with autosomal recessive inheritance.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
7.9 TPM
Tireoide
7.7 TPM
Testículo
7.2 TPM
Nervo tibial
7.0 TPM
Cerebelo
6.5 TPM
OUTRAS DOENÇAS (3)
mitochondrial complex I deficiency, nuclear type 17Fanconi renotubular syndrome 5primary Fanconi syndrome
HGNC:28625UniProt:Q330K2
MRM2rRNA methyltransferase 2, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

S-adenosyl-L-methionine-dependent 2'-O-ribose methyltransferase that catalyzes the formation of 2'-O-methyluridine at position 1369 (Um1369) in the 16S mitochondrial large subunit ribosomal RNA (mtLSU rRNA), a universally conserved modification in the peptidyl transferase domain of the mtLSU rRNA (PubMed:25009282, PubMed:25074936, PubMed:35177605). This activity may require prior 2'-O-methylguanosine modification at position 1370 (Gm1370) by MRM3 (PubMed:35177605). Essential for late-stage assem

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
rRNA modification in the mitochondrion
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 17

An autosomal recessive mitochondrial disorder characterized by childhood onset of rapidly progressive encephalopathy, stroke-like episodes, lactic acidosis, hypocitrullinemia, multiple defects of oxidative phosphorylation, mitochondrial complex I and IV deficiency, and reduced mtDNA copy number.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
49.9 TPM
Fibroblastos
31.2 TPM
Baço
22.1 TPM
Útero
20.5 TPM
Testículo
20.4 TPM
OUTRAS DOENÇAS (1)
mitochondrial DNA depletion syndrome 17
HGNC:HGNC:16352UniProt:Q9UI43
SLC25A4ADP/ATP translocase 1Disease-causing germline mutation(s) inModerado
FUNÇÃO

ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (PubMed:21586654, PubMed:27693233, PubMed:23173940, PubMed:30046662). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By si

LOCALIZAÇÃO

Mitochondrion inner membraneMembrane

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 2

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
563.9 TPM
Coração - Átrio
428.0 TPM
Músculo esquelético
370.5 TPM
Cérebro - Hemisfério cerebelar
138.9 TPM
Esôfago - Muscular
110.1 TPM
OUTRAS DOENÇAS (5)
mitochondrial DNA depletion syndrome 12B (cardiomyopathic type), autosomal recessivemitochondrial DNA depletion syndrome 12A (cardiomyopathic type), autosomal dominantprogressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2autosomal dominant progressive external ophthalmoplegia
HGNC:10990UniProt:P12235

Variantes genéticas (ClinVar)

1,371 variantes patogênicas registradas no ClinVar.

🧬 FH: NM_000143.4(FH):c.1037G>C (p.Gly346Ala) ()
🧬 FH: NM_000143.4(FH):c.708del (p.Gln237fs) ()
🧬 FH: GRCh38/hg38 1q43-44(chr1:237818970-248924793)x1 ()
🧬 FH: NM_000143.4(FH):c.1462G>T (p.Glu488Ter) ()
🧬 FH: NM_000143.4(FH):c.422G>A (p.Trp141Ter) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 848 variantes classificadas pelo ClinVar.

509
297
42
Patogênica (60.0%)
VUS (35.0%)
Benigna (5.0%)
VARIANTES MAIS SIGNIFICATIVAS
ATG12: NM_004707.4(ATG12):c.324T>G (p.Phe108Leu) [Likely pathogenic]
ATG12: NM_004707.4(ATG12):c.235C>T (p.Arg79Ter) [Likely pathogenic]
ATG12: NM_004707.4(ATG12):c.413C>T (p.Ala138Val) [Likely pathogenic]
TK2: NM_004614.5(TK2):c.296A>G (p.Tyr99Cys) [Likely pathogenic]
TK2: NM_004614.5(TK2):c.676_677dup (p.Pro227fs) [Likely pathogenic]

Vias biológicas (Reactome)

107 vias biológicas associadas aos genes desta condição.

Citric acid cycle (TCA cycle) Mitochondrial protein degradation Mitochondrial ribosome-associated quality control Mitochondrial tRNA aminoacylation Synthesis of wybutosine at G37 of tRNA(Phe) Interconversion of nucleotide di- and triphosphates TP53 Regulates Metabolic Genes Degradation of cysteine and homocysteine Detoxification of Reactive Oxygen Species Ubiquinol biosynthesis tRNA processing in the mitochondrion tRNA modification in the mitochondrion rRNA processing in the mitochondrion Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Transcriptional regulation by RUNX3 TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Cell Death Genes Defective homologous recombination repair (HRR) due to PALB2 loss of function Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function NPAS4 regulates expression of target genes Intracellular oxygen transport Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Formation of ATP by chemiosmotic coupling Mitochondrial translation termination Cristae formation Respiratory electron transport Complex I biogenesis Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol alpha-linolenic acid (ALA) metabolism Beta-oxidation of pristanoyl-CoA Beta-oxidation of very long chain fatty acids Peroxisomal protein import TYSND1 cleaves peroxisomal proteins Protein lipoylation Complex III assembly Neutrophil degranulation Purine salvage Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid PDH complex synthesizes acetyl-CoA from PYR Lanosterol biosynthesis Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Activation of caspases through apoptosome-mediated cleavage Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery Mitochondrial translation initiation Mitochondrial translation elongation Transcriptional regulation by RUNX2 NOTCH2 Activation and Transmission of Signal to the Nucleus Signaling by NOTCH2 Response of endothelial cells to shear stress Developmental Cell Lineages SARS-CoV-2 Infection Downregulation of ERBB2 signaling Regulation of CDH1 Expression and Function Regulation of RUNX2 expression and activity Transcriptional activation of mitochondrial biogenesis Strand-asynchronous mitochondrial DNA replication Defective MUTYH substrate processing Defective Base Excision Repair Associated with NEIL1 Signaling by MET Virion Assembly and Release Virion Assembly and Release IKK complex recruitment mediated by RIP1 Transcriptional regulation by RUNX1 Cytoprotection by HMOX1 Complex IV assembly Azathioprine ADME Glycine degradation Branched-chain amino acid catabolism OGDH complex synthesizes succinyl-CoA from 2-OG OADH complex synthesizes glutaryl-CoA from 2-OA BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV Loss-of-function mutations in DBT cause MSUD2 Loss-of-function mutations in DLD cause MSUD3/DLDD Branched-chain ketoacid dehydrogenase kinase deficiency H139Hfs13* PPM1K causes a mild variant of MSUD Mitochondrial protein import Processing of SMDT1 Mitochondrial iron-sulfur cluster biogenesis Maturation of TCA enzymes and regulation of TCA cycle Acyl chain remodeling of CL Beta oxidation of myristoyl-CoA to lauroyl-CoA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids Beta oxidation of palmitoyl-CoA to myristoyl-CoA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA Beta oxidation of octanoyl-CoA to hexanoyl-CoA Beta oxidation of hexanoyl-CoA to butanoyl-CoA Pyruvate metabolism Mitochondrial RNA degradation Mitochondrial mRNA modification RHOG GTPase cycle HARS2 histidine + tRNA(His) + ATP => His-tRNA(His) + AMP + pyrophosphate Pregnenolone biosynthesis Endogenous sterols Electron transport from NADPH to Ferredoxin Defective CYP11A1 causes AICSR Heme biosynthesis rRNA modification in the mitochondrion Mitochondrial Uncoupling Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 22
1Fase 12
·Pré-clínico8
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 13 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença mitocondrial

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

8 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

448 ensaios clínicos encontrados, 10 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.735 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.735

#1

Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.

Pediatric neurology2026 Feb 13

Before diagnostic whole exome sequencing, monogenic/chromosomal developmental and epileptic encephalopathies (DEEs) were frequently misdiagnosed as mitochondrial disorders (MDs) with epilepsy, due to overlapping clinical and biochemical features. Assessing muscle functional assays in patients with a genetic diagnosis and epilepsy offers a unique opportunity to explore mitochondrial dysfunction in monogenic/chromosomal DEEs, in comparison to the mitochondrial dysfunction observed in genetically confirmed MDs. In this retrospective cohort study, clinical and biochemical data were extracted from patients suspected of MD with epilepsy who underwent muscle/fibroblast biopsy (2005-2015). Patients were classified into four groups based on the final diagnosis. Mitochondrial Disease Criteria scores were assigned. Statistical analyses were conducted using Fisher's exact, analysis of variance, and Kruskal-Wallis tests. Of 27 included participants, eleven (40.7%) had DEEs, four (14.8%) had genetically confirmed MDs, eight (29.6%) were suspected MD cases without genetic confirmation, and four (14.8%) had nonmitochondrial metabolic diseases. Mitochondrial dysfunction was common across all groups; 85% of participants met probable/definite Mitochondrial Disease Criteria, over 70% had elevated plasma lactate (>2.5 mmol/L), and 92% exhibited impaired adenosine triphosphate production. Surprisingly, moderate to severe complex dysfunction was observed in all groups except genetically confirmed MDs. Our findings indicate that mitochondrial dysfunction is prevalent in nonmitochondrial DEEs. Patients previously diagnosed with an MD based only on muscle/fibroblast biopsy may benefit from whole exome sequencing to identify genetic variants, for which targeted therapy may be available. Future research should explore whether treatment or prognosis of nonmitochondrial DEEs should be tailored to improve mitochondrial function.

#2

COG5 deficiency disrupts cellular copper homeostasis and underlies the impaired mitochondrial OXPHOS function.

PLoS genetics2026 Mar

COG5, a subunit of the conserved oligomeric Golgi (COG) complex, plays a critical role in retrograde trafficking within the Golgi apparatus. Dysfunction of COG5 is associated with various human disorders, yet the underlying pathogenic mechanisms remain poorly understood. To investigate the mechanisms, we conducted proteomic analyses using COG5-deficient and rescue cell models, which revealed a potential link between COG5 dysfunction and mitochondrial oxidative phosphorylation (OXPHOS) deficiency. Using COG5-deficient cell models and patient-derived cells harboring COG5 variants, we biochemically validated the involvement of COG5 in mitochondrial OXPHOS, particularly in the regulation of complex I content. These models also exhibited elevated cellular copper levels. Notably, the significant reduction in OXPHOS complexes could be rescued by either restoring COG5 expression or administering a copper chelator. We further demonstrated that excessive cellular copper disrupts the function of mitochondrial iron-sulfur clusters, potentially leading to complex I assembly defects. Additionally, we identified a patient with biallelic COG5 variants presenting with a distinct subtype of mitochondrial disease (Leigh syndrome), a phenotype not previously associated with COG5-related disorders. These findings provide novel mechanistic insights into the role of COG5, extending beyond its established function in Golgi-mediated glycosylation modifications. Our results underscore the importance of COG5 in mitochondrial function through a copper-dependent pathway, offering new perspectives on its contribution to cellular homeostasis and disease pathogenesis.

#3

Emerging neurological and cognitive symptoms in patients with late-onset ornithine transcarbamylase deficiency: a narrative review.

Metabolic brain disease2026 Mar 13

Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder associated with mild-to-severe neurological/cognitive symptoms that impact quality of life. Most patients are diagnosed with late-onset OTCD after 28 days of age. Emerging symptoms in adolescents and adults may not be recognized as effects of hyperammonemia, a common and potentially lethal complication of OTCD, and may contribute to substantial burden even when patients are diagnosed and treated. However, current reviews do not address this burden. Our aim is to raise awareness of neurological/cognitive manifestations of late-onset OTCD in adolescents and adults to reduce diagnostic delays and improve outcomes. Acutely, patients can present with signs of neurological impairment and psychiatric manifestations, which may be associated with a specific trigger or without known cause. Cognitive changes are more likely to be subacute or chronic, and onset may occur after hyperammonemia. As many late-onset OTCD cases are identified after presenting to emergency departments or primary care providers (often followed by hospital admission), education of frontline providers is needed to drive awareness, recognize symptoms, and improve patient care. [Image: see text]

#4

Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease.

Neurology. Genetics2026 Apr

POLG-related disorders exhibit marked phenotypic heterogeneity and frequent clinical overlap, often leading to delayed diagnosis. A precise delineation of their clinical spectrum, natural history, and the identification of reliable biomarkers is essential to improve diagnostic accuracy and guide therapeutic development. We analyzed a cohort of 34 patients with confirmed pathogenic POLG variants, assessing clinical phenotypes, molecular findings, and biomarkers (plasma growth differentiation factor-15 [GDF15] in 16, plasma neurofilament light chain [NF-L] in 14, and mitochondrial DNA [mtDNA] copy number in muscle in 16). Thirty four patients (0.6-71 years) from 33 families were included. Juvenile/adult onset (12-40 years) was the most common presentation (62%). The predominant phenotypic categories were ataxia-neuropathy spectrum ([ANS], 44%), autosomal recessive PEO-plus (arPEO-plus, 26%), and autosomal dominant PEO-plus ([adPEO-plus], 15%), with frequent phenotypic overlap. Recessive inheritance accounted for 74% of cases, with the most common variants being p.([Thr251Ile; Pro587Leu]) paired on 1 allele, p.(Ala467Thr), and p.(Trp748Ser). Dominant variants were associated with milder, primarily myopathic phenotypes. The most common dominant variant was p.(Tyr955Cys). No clear genotype-phenotype correlations were identified among recessive variants. Compared with previously reported cohorts, our patients exhibited a lower prevalence of seizures, hepatopathy, and stroke-like episodes. GDF15 was elevated in 87.5% of patients, with a mean level of 3,315 pg/mL (±1,559.79), showing no significant differences between myopathic and ANS phenotypes, supporting its role as a general biomarker of mitochondrial dysfunction. NF-L was elevated in 78.6% of tested individuals but did not correlate with phenotype or clinical severity (as per Newcastle Mitochondrial Disease Adult Scale score).On average, muscle mtDNA copy number in patients was 76% of that observed in controls, with no differences by phenotype or inheritance pattern. All but 1 patient exhibited multiple mtDNA deletions, likely representing the primary mechanism of oxidative phosphorylation dysfunction rather than mtDNA depletion. POLG-related disorders demonstrate extensive clinical variability with no consistent genotype-phenotype correlation. GDF15 and NF-L may serve as useful, though nonspecific, biomarkers of mitochondrial and neuroaxonal dysfunction, respectively. Prospective studies incorporating advanced molecular profiling are essential to establish reliable outcome measures and inform future therapeutic strategies.

#5

Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.

Cell2026 Mar 19

Mitochondrial disease encompasses inherited disorders affecting mitochondrial function. A severe and untreatable form of mitochondrial disease is Leigh syndrome (LS), causing psychomotor regression and metabolic crises. To accelerate drug discovery for LS, we screen a library of 5,632 repurposable compounds in neural cells from LS-patient-derived induced pluripotent stem cells (iPSCs). We identify phosphodiesterase type 5 (PDE5) inhibitors as leads and prioritize sildenafil for its clinical safety. Sildenafil corrects mitochondrial membrane potential defects, restores neurodevelopmental pathways, and normalizes calcium responses in LS brain organoids. In small and large mammalian models of LS, sildenafil extends lifespan and ameliorates disease phenotypes. Off-label treatment on an individual basis with sildenafil in six LS patients improves their motor function and resistance to metabolic crises. Collectively, the findings highlight the potential of iPSC-driven drug discovery and position sildenafil as a promising drug candidate for mitochondrial disease.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.205 artigos no totalmostrando 196

2026

Mitochondrial dysfunction in urologic disease.

Prostate cancer and prostatic diseases
2026

m.10010T>C Mitochondrial Disease: A Case Report With Hypoparathyroidism and Review of the Literature.

American journal of medical genetics. Part A
2026

Integrated molecular and clinical profiling of primary mitochondrial oxidative phosphorylation disorders in an Indian cohort: Insights from genetics, neuroimaging, and machine learning.

Mitochondrion
2026

Metabolic Myopathies and HyperCKemia in Adulthood: A Clinical Approach to Diagnosis and Management.

Journal of clinical medicine
2026

Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.

Pediatric neurology
2026

COG5 deficiency disrupts cellular copper homeostasis and underlies the impaired mitochondrial OXPHOS function.

PLoS genetics
2026

Emerging neurological and cognitive symptoms in patients with late-onset ornithine transcarbamylase deficiency: a narrative review.

Metabolic brain disease
2026

Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease.

Neurology. Genetics
2026

From disease prevention to fertility treatment: rethinking the use of mitochondrial donation for oocyte-related infertility in the light of safety and efficacy.

Human reproduction (Oxford, England)
2026

Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.

Cell
2026

Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document.

European journal of heart failure
2026

The goal attainment scale in primary mitochondrial disease: Construct validity and lessons learned from a randomized controlled trial.

Molecular genetics and metabolism
2026

Surgical Treatment for Spinal Scoliosis in Patient With Mitochondrial Disease After Heart Transplantation: A Case Report and Literature Review.

Case reports in orthopedics
2026

Association of mitochondrial genetic background with pS65-Ub in Lewy body disease.

Acta neuropathologica
2026

Mitochondrial complex assembly in epilepsy of primary mitochondrial disease origin.

Seizure
2026

[Decreased plasma citrulline is a biochemical marker in newborn screening for MT-ATP6-associated mitochondrial disease: two case reports and a literature review].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2026

A Novel Truncating Pathogenic Variant in RRM2B in a Kurdish Family With Autosomal-Dominant Chronic Progressive External Ophthalmoplegia Plus (PEOA5).

Journal of clinical neuromuscular disease
2026

Charting the phenotypic landscape of mitochondrial diseases through a systematic evaluation of pathogenic mitochondrial DNA and nuclear gene variants.

Genetics in medicine : official journal of the American College of Medical Genetics
2026

Mesenchymal stem cell mitochondrial transfer effectively protects Leber's Hereditary Optic Neuropathy (LHON) mutant cells from mitochondrial damage.

Acta histochemica
2026

A case report of combined oxidative phosphorylation deficiency 35 (COXPD35) in Palestine caused by novel compound heterozygous TRIT1 variants.

Medicine
2026

Recessive PPTC7 deficiency triggers excessive mitophagy to cause a severe inborn error of metabolism with hypomyelinating leukodystrophy.

Research square
2026

The Citric Acid Cycle Modulates Neurologic Health and Is a Therapeutic Target of Dietary and Genetic Modification in Metabolic Disease.

Genes
2026

Mainstreaming genomic testing for mitochondrial disease in Australia.

European journal of human genetics : EJHG
2026

MITO-VATION: Feasibility of a technology-supported structured home exercise program in Mitochondrial Disease.

PLOS digital health
2025

Risk of sudden cardiac death due to inorganic pyrophosphate A2 deficiency in a Pakistani infant: Diagnostic and management challenges in low-resource settings.

Annals of pediatric cardiology
2026

Novel Biallelic LIG3 Mutations Causing Lethal Phenotype With Immunodeficiency.

American journal of medical genetics. Part A
2026

Muscle biopsy and mitochondrial disease criteria as diagnostic tools for paediatric patients presenting with neuromuscular phenotypes: highlighting the role of secondary mitochondrial dysfunction.

Neuromuscular disorders : NMD
2026

Nutrient and endocrine factors affecting impaired growth in pediatric mitochondrial diseases.

Endocrinology, diabetes & metabolism case reports
2026

4,5-dihydroxyhexanoic acid is a robust circulating and urine marker of mitochondrial disease and its severity.

bioRxiv : the preprint server for biology
2026

Hypertrophic cardiomyopathy as a novel phenotypic feature of NSUN3-related mitochondrial disease: a case report with review of the literature.

Journal of pediatric endocrinology & metabolism : JPEM
2026

From genotype to outcome: Zygosity-specific insights in 63 cases of CLPB-related mitochondrial disease.

Molecular genetics and metabolism
2026

Phenotypic description and functional characterization of the mitochondrial disease associated with the SFXN4 gene.

Mitochondrion
2026

Identifying NDUFA12 mutation in a Saudi family: An unusual presentation of mitochondrial Complex I deficiency mimicking as idiopathic intracranial hypertension in a patient with papilledema and visual loss.

Journal of family & community medicine
2026

A novel tRNASer(AGY) 12244G > a variant impairs mitochondrial function and presents with classical MELAS phenotype.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Neuronal intranuclear inclusion disease: a diagnostic pitfall for MELAS.

BMC neurology
2026

MELAS Syndrome Presenting with Hypertrophic Cardiomyopathy and Advanced Heart Failure: A Multisystem Diagnostic Challenge.

Journal of clinical medicine
2026

Short telomeres in mitochondrial DNA depletion disorders.

Mitochondrion
2026

A Case of Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia (MLASA Syndrome) and Long QT Interval in a 10-Year-Old Saudi Child.

Saudi journal of medicine & medical sciences
2026

Early diagnosis of fetal ganglionic eminence cysts: imaging, outcome and genetic associations, revealing role of mitochondrial dysfunction.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
2026

Super-Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review.

Annals of clinical and translational neurology
2026

Case Report: Simultaneous pancreas-kidney transplantation in MELAS: first reported case with 5-year follow-up.

Frontiers in transplantation
2026

Largely Distinct Post-Translational Modifications Differentiate Skeletal Muscle Wasting Caused by Cancer, Dexamethasone and Aging.

Journal of cachexia, sarcopenia and muscle
2026

Leigh Syndrome Pathomechanism Involves Region-Specific Innate Immune Activation in Ndufs4 Knockout Mice.

Cellular and molecular neurobiology
2026

Expanding the cognitive spectrum of mitochondrial diseases.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Mitochondrial DNA release and inflammation in mitochondrial disease pathogenesis.

Brain : a journal of neurology
2026

Bridging gaps in mitochondrial disease diagnosis: the role of advanced biomarker discovery.

Journal of molecular medicine (Berlin, Germany)
2026

Spatial mapping of CoQ10 repletion by BPM31510 in a genetic mouse model (Coq4F147C) of coenzyme Q deficiency.

Journal of lipid research
2026

[Super-refractory status epilepticus caused by hereditary mitochondrial disease].

Ugeskrift for laeger
2026

Impaired mitochondrial morphology and respiratory dysfunction in human induced pluripotent stem cells with mitochondrial tRNA mutations (m.3243A>G and m.14739G>A).

Orphanet journal of rare diseases
2026

Outcomes of kidney transplantation in three patients with single large-scale mitochondrial DNA deletion syndromes.

Molecular genetics and metabolism
2026

RTN4IP1 mutation and endocrine failure: clinical features and possible benefits of coenzyme Q10.

Endocrine connections
2026

Optical and Microdialysis Monitoring of Succinate Prodrug Treatment in a Rotenone-Induced Model of Mitochondrial Dysfunction in Swine.

Metabolites
2026

Targeting mitochondrial deubiquitinase USP30 to induce mitophagy in heteroplasmic mitochondrial diseases.

Pharmacological reports : PR
2026

Drivers of Diagnostic Delay in Mitochondrial Disease: Missed Recognition of Canonical Features.

JIMD reports
2026

Sensitivity of primary mitochondrial disease fibroblasts to ferroptosis: The role of intracellular iron.

Mitochondrion
2026

Deficiency of the NAD(P)HX metabolic repair system: a treatable mitochondrial disease.

Orphanet journal of rare diseases
2026

Ultrasound-assisted gene therapy mitigates Leigh syndrome pathology.

Brain : a journal of neurology
2026

ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.

Current opinion in neurobiology
2026

Multiple Mitochondrial Dysfunction Syndrome Caused by IBA57 Gene Mutation: A Case Report and Literature Review.

Molecular genetics & genomic medicine
2026

Ethylmalonic encephalopathy caused by biallelic truncating variants in ETHE1: A case report.

SAGE open medical case reports
2026

NMR-based urinary biomarkers in pediatric primary mitochondrial disorders and chronic kidney disease: shared mitochondrial dysfunction, diverging biosignatures.

Metabolomics : Official journal of the Metabolomic Society
2026

Clinical and Genotypic Spectrum of Twinkle-Related Disorders: Insights From a Multinational Cohort Study.

Neurology
2026

Energy Metabolism Under Stress: Late-Stage Leigh Syndrome Reveals Profound Cardiometabolic Perturbations in Ndufs4 KO Mice.

Journal of inherited metabolic disease
2026

Evaluation of MASSARRAY technique in detecting mitochondrial disease mutations.

Clinica chimica acta; international journal of clinical chemistry
2025

Mitochondrial Disorder in a Child With Brainstem Lesions Mimicking Thiamine Deficiency.

Cureus
2026

Homozygous MGME1 Variant in Turkish Siblings: First Reported Case With Successful Heart Transplantation, Expanding the Clinical Spectrum of MGME1-Related Mitochondrial Disease.

American journal of medical genetics. Part A
2026

SWATH-MS reveals tissue-specific proteomic changes in a Leigh syndrome mouse model.

Molecular genetics and metabolism
2026

Mitochondrial DNA Maintenance Defects: Clinical, Imaging, and Genetic Spectrum of Four Patients from a Single Tertiary Care Centre.

Annals of Indian Academy of Neurology
2025

The Path to Precision Medicine in Leigh Syndrome Spectrum: A Four-Decade Chronicle of Genetic Discovery and Targeted Treatment.

Frontiers in bioscience (Scholar edition)
2025

Mapping metabolic dependences and capacities using ATP as a biomarker.

Research square
2026

Ferroptosis susceptibility in primary coenzyme Q10 deficiency: Cellular insights from patient fibroblasts and clinical course of six individuals.

Brain & development
2025

Profiles of paediatric patients experiencing stroke-like episodes associated with mitochondrial disease.

Frontiers in neurology
2025

Ferroptosis is a novel pathogenic mechanism of FDXR-related disease via disruption of the NRF2 pathway.

Cell death discovery
2025

From Severe Neonatal Encephalopathy to Slowly Neurologic Progressive Disease: Pyruvate Dehydrogenase Deficiency Related to PDHA1 Variants.

Journal of child neurology
2025

Stroke-like lesion and status epilepticus in a child with NARS2-related combined oxidative phosphorylation deficiency 24.

Frontiers in neurology
2025

Comprehensive Iranian guidelines for the diagnosis and management of mitochondrial disorders: an evidence- and consensus-based approach.

Orphanet journal of rare diseases
2026

Mutant CHCHD10 disrupts cytochrome c oxidation and activates mitochondrial retrograde signaling.

EMBO molecular medicine
2025

Quantifying variability of mitochondrial markers in m3243A > G myopathy.

Scientific reports
2026

Counseling and Prognostic Challenges in Survivorship and Mortality in Primary Mitochondrial Disease: Reshaping a Once Bleak Landscape.

Pediatric neurology
2026

Identification of Intronic Variants in NDUFA3 as a Cause of Leigh Syndrome by Whole Genome Sequencing and RNA Sequencing.

Neurology. Genetics
2025

Full recovery of vision following early and intensive hemodialysis in an 18-year-old woman with methylmalonic acidemia-related optic neuropathy.

Molecular genetics and metabolism reports
2026

Functional Screening of NDUFAF6 Variants in Knockout Cells and Complementary Computational Analysis.

Journal of clinical laboratory analysis
2025

Partial restoration of mitochondrial dysfunction by AAV-Ant1 protects from dilated cardiomyopathy in Ant1-/- plus mtDNA mutant mice.

Nature communications
2025

Mitochondrial HMG-CoA Synthase Deficiency Presenting as Pediatric Metabolic Stroke: A Case Report of a Novel Homozygous HMGCS2 (p.Ile56Asn) Variant.

Clinical case reports
2025

An Alternative Metabolic Pathway of Glucose Oxidation Induced by Mitochondrial Complex I Inhibition: Serinogenesis and Folate Cycling.

International journal of molecular sciences
2025

Clinical insights into mitochondrial retinopathy: A case report on m.3243A>G mutation and macular dystrophy.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2025

Mitochondria-targeted gene delivery using fluorinated lipid nanoparticles to alleviate Leber's hereditary optic neuropathy.

Nature communications
2025

Vacuolar-type H+-ATPase-mediated extra-organellar buffering resolves mitochondrial dysfunction.

Nature communications
2025

Examining saliva proteomic dynamics in mitochondrial diseases from a perspective of intrinsic health.

Scientific reports
2025

Dietary lipid content modifies wah-1/AIFM1-associated phenotypes via LRK-1 and DRP-1 expression in C. elegans.

Nature communications
2026

Exercise-mediated regulation of mitochondrial dynamics in aging muscle: implications for mitochondrial diseases.

Molecular and cellular biochemistry
2025

Cardiac magnetic resonance findings in mitochondrial disease: a guide for clinicians.

European heart journal. Imaging methods and practice
2025

Mitochondrial Disease Diagnosed Following Preterm Birth at 29 Weeks of Gestation and Postpartum Heart Failure: A Case Report and Literature Review.

Clinical case reports
2025

Dysfunctional LHX6 pallido-subthalamic projections mediate epileptic events in a mouse model of Leigh syndrome.

The Journal of clinical investigation
2025

Kidney transplantation in mitochondrial diseases: a systematic review.

Pediatric nephrology (Berlin, Germany)
2025

SLP2/PHB Aggregates in ALS Mouse Models and Patients: Implications Beyond CHCHD10-Associated Motor Neuron Disease.

International journal of molecular sciences
2025

From Congenital Torticollis to Leigh Syndrome: A Case Report of Diagnostic Evolution in an Infant.

Children (Basel, Switzerland)
2025

Mitochondrial Nephropathy With m.5538G>A Mutation Within the tRNA-Trp Region Assessed by Mitochondrial Function Analysis: A Case Report.

Nephrology (Carlton, Vic.)
2025

Fontaine progeroid syndrome with neonatal mitochondrial disease.

Human genome variation
2025

Expanding research and care for Leigh syndrome: efforts of a patient-led advocacy organization.

Research involvement and engagement
2025

CRISPR/Cas9-mediated editing of MIC13 in human induced pluripotent stem cells: A model for mitochondrial hepato-encephalopathy.

Stem cell research
2025

Hypocitrullinemia as an Early Diagnostic Biomarker for MT-ATP6 Mitochondrial Diseases.

Journal of molecular neuroscience : MN
2025

Computational design of a high-precision mitochondrial DNA cytosine base editor.

Nature structural & molecular biology
2025

A Scoping Review of POLG-Related Cerebellar Ataxia: Insights and Clinical Perspectives.

Tremor and other hyperkinetic movements (New York, N.Y.)
2025

The genotypic and phenotypic landscape of PDHA1-related pyruvate dehydrogenase complex deficiency.

Brain : a journal of neurology
2025

Mitochondrial DNA Replication and Disease: A Historical Perspective on Molecular Insights and Therapeutic Advances.

International journal of molecular sciences
2025

Perioperative Care of a Child With Combined Oxidative Phosphorylation Deficiency 6: Total Intravenous Anesthesia With Remimazolam.

Journal of medical cases
2025

Mild pancreatic fibrosis with preserved exocrine function and increased visceral adipose tissue in m.3243A>G carriers: A magnetic resonance imaging study.

Molecular genetics and metabolism
2025

National diagnostic gaps for TK2 Deficiency in Italy: insights from the AIM Multicenter Survey.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2025

From Castro to Quantum Mechanics: Marching Through Tunnels With Reactive Oxygen Species.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2025

Mitochondrial Leigh syndrome: the state of the art.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2026

Natural products that suppress 2-deoxy-d-glucose-induced cell death as potential drug seeds for mitochondrial diseases.

Bioorganic & medicinal chemistry
2025

Mitochondrial Activation and Therapeutics: Innovations in Cell- and Organelle-Specific Medicine.

Biological & pharmaceutical bulletin
2025

Gut instinct: microbiome as a modifiable target in the management of neurologic symptoms in myoclonic epilepsy with ragged-red fibers (MERRF).

Annals of medicine and surgery (2012)
2026

Advancing a sensitive method for measuring mitochondrial ATP production in small muscle biopsy samples.

Analytical biochemistry
2025

Mechanisms of Mitochondrial Impairment by SARS-CoV-2 Proteins: A Nexus of Pathogenesis with Significant Biochemical and Clinical Implications.

International journal of molecular sciences
2025

Long-Term Postural Orthostatic Tachycardia Syndrome Outcomes Survey: Educational, Economic, and Social Impact.

Journal of the American Heart Association
2025

Super mitochondria-enriched extracellular vesicles enable enhanced mitochondria transfer.

Nature communications
2026

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm.

Diabetes, obesity & metabolism
2025

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes.

Journal of visualized experiments : JoVE
2025

Signs, symptoms, and health-related quality of life in MELAS: measuring what's important from the patient and clinician perspectives.

Journal of patient-reported outcomes
2025

Case Report: Aveir implantation in an 8.7-year-old, 25-kg pediatric patient with mitochondrial disease via internal jugular vein.

Frontiers in cardiovascular medicine
2025

Lactic acidosis, rhabdomyolysis, and hyperammonemia: Atypical presentation in a new patient with PDE-ALDH7A1 defect.

Molecular genetics and metabolism reports
2025

Macular OCT inner retinal changes reflect CNS involvement in m.3243A>G disease.

BMJ neurology open
2026

Clinical characteristics and hearing impairment in carriers of the m.3243 A > G variant.

Journal of human genetics
2026

From Biogenesis to Breakdown: How Protein Biogenesis and Quality Control Failures Drive Mitochondrial Disease.

Molecular and cellular biology
2025

Region-Specific Quantification of 2-Hydroxyglutarate Enantiomers in Murine Brain during Mitochondrial Complex I Deficiency.

ACS chemical neuroscience
2025

Evaluation of Serum FGF21 Levels in Patients with Mitochondrial Aminoacyl-tRNA Synthetase Deficiency.

International journal of molecular sciences
2025

Evaluation of atypical antipsychotic-induced mitochondrial dysfunction in patients with schizophrenia: a randomised controlled trial protocol.

BMJ open
2025

[Long-term efficacy observation of nicotinamide in the treatment of early-onset progressive encephalopathy with brain edema and (or) leukoencephalopathy-2 caused by NAXD gene variation].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

Pathogenesis of mtDNA point mutation m.10191T>C affecting complex I function is a multifactorial process leading to metabolic remodeling of mitochondria.

Biochimica et biophysica acta. Molecular basis of disease
2025

Cardiac transplant outcomes in a pediatric patient with novel homozygous variants in TOP3Α causing mitochondrial dysfunction.

Molecular genetics and metabolism
2025

From stroke workup to mitochondrial disease: A case report of MELAS.

Radiology case reports
2026

The Case of a 25-Year-Old Woman With Isolated Head Tremor.

Annals of clinical and translational neurology
2025

First approved drug for mitochondrial disease raises hopes for more.

Science (New York, N.Y.)
2025

Outcomes misaligned in mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): implications for trial design.

Brain communications
2025

Lithium nickel manganese cobalt oxide particles cause developmental neurotoxicity in Caenorhabditis elegans.

Environmental science. Advances
2025

A mouse model of MEPAN demonstrates a role for mitochondrial fatty acid synthesis in iron-sulfur cluster and supercomplex formation.

Proceedings of the National Academy of Sciences of the United States of America
2025

Establishment of human Leber's hereditary optic neuropathy model using iPSC-derived retinal organoids.

Frontiers in cellular neuroscience
2025

Health-related quality of life in patients with mitochondrial disease and their carers.

Journal of medical genetics
2025

Transcriptomic Signatures of Mitochondrial Dysfunction in Autism: Integrated mRNA and microRNA Profiling.

Genes
2025

The First Heterozygous TWNK Nonsense Mutation Associated with Progressive External Ophthalmoplegia: Evidence for a New Piece in the Puzzle of Mitochondrial Diseases.

Biomolecules
2025

Gene therapy and mRNA drugs approach for mitochondrial OXPHOS deficiencies.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

Widespread and progressive brain atrophy is a common feature in patients with mitochondrial disease.

Journal of neurology
2025

Neuroimaging features of familial MT-TK related mitochondrial disease in a child.

BMJ case reports
2025

Mitochondrial Transplantation: A Paradigm Shift in Osteoporosis Therapy.

International journal of nanomedicine
2025

Compartmentalized thymidine phosphorylation by mitochondrial nucleotide kinases TK2 and CMPK2.

The Journal of biological chemistry
2025

[Clinical characteristics analysis of mitochondrial short-chain enoyl-CoA hydratase 1 deficiency with ECHS1 gene c.489G>A compound heterozygous variants].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

Meclizine rescues cardiac function and mitochondrial ultrastructure by ATP- and glycolysis-independent mechanisms in a genetic model of mitochondrial energy dysfunction.

bioRxiv : the preprint server for biology
2025

Mitochondrial Diseases: Molecular Pathogenesis and Therapeutic Advances.

MedComm
2025

Genetic background of neurological disorders with basal ganglia calcification.

Journal of neurology
2025

Motor Neuropathy in a Patient With Mitochondrial Disease and a Novel TTC19 Variant: An Underrecognized Phenotypic Feature.

Journal of the peripheral nervous system : JPNS
2025

Mitochondria-Associated Pathways in Cancer and Precancerous Conditions: Mechanistic Insights.

International journal of molecular sciences
2025

Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data.

Annals of clinical and translational neurology
2025

OXPHOS complex deficiency in congenital myopathy: A systematic review.

European journal of clinical investigation
2025

Structural insights into DdCBE in action enable high-precision mitochondrial DNA editing.

Molecular cell
2025

Estradiol alleviates disease phenotypes caused by m.3635G > A mutation by activating mitochondrial biogenesis and PINK1-Parkin mediated mitophagy in iPSC-derived retinal pigment epithelium cells.

Cellular signalling
2025

Preclinical and first-in-human evidence of 4-hydroxybenzoic acid for mitochondrial COQ2 deficiency.

Brain : a journal of neurology
2025

ADSL deficiency is a secondary mitochondrial disease affecting organelle homeostasis and ERK2/AKT signaling in a linear genotype-phenotype relation.

Cell reports
2026

Mitochondrial Complex V Deficiency Caused by a Homozygous Splice Variant in ATP5PO.

American journal of medical genetics. Part A
2025

Pyrimidine Nucleos(t)ide Therapy in Patients With Thymidine Kinase 2 Deficiency: A Multicenter Retrospective Chart Review Study.

Neurology
2025

Metformin may alter the course of Leber's hereditary optic neuropathy: a case report.

Frontiers in medicine
2025

Alterations in mitochondrial base editors enhance targeted editing efficiency for mouse model generation.

Molecular therapy. Nucleic acids
2025

Late-onset Leber's hereditary optic neuropathy and antiandrogens for prostate cancer: is there a causative link?

Frontiers in neurology
2025

Neonatal diabetes mellitus is a significant feature of COXPD-24 caused by recessive NARS2 variants.

Diabetic medicine : a journal of the British Diabetic Association
2025

Retinal multimodal-imaging and functional tests in a mitochondrial disease with focal and segmental glomerulosclerosis.

International journal of ophthalmology
2025

RTN4IP1 is required for the final stages of mitochondrial complex I assembly and CoQ biosynthesis.

The EMBO journal
2025

Genetic Dissection of Energy Deficiency in Autism Spectrum Disorder.

Genes
2025

Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study.

Life (Basel, Switzerland)
2025

Selective muscle MRI changes in a patient with a rare mitochondrial DNA variant causing myoclonic epilepsy with ragged red fibres.

Neuromuscular disorders : NMD
2025

Dysfunctional Electron Transport Chain Assembly in COXPD8.

Journal of cardiovascular development and disease
2025

Quality control at the powerhouse: mitochondrial proteostasis dysfunction and disease.

Biochemical Society transactions
2025

Nonischemic Cardiomyopathy in Adult-Onset PPA2-Deficient Mitochondrial Disease.

JACC. Case reports
2025

Recurrent Syncope and Drooping Eyes in a Young Woman: Kearns-Sayre Syndrome.

JACC. Clinical electrophysiology
2025

The homoplasmic MT-TK m.8357T > C mtDNA variant as a cause of multiorgan mitochondrial disease.

Mitochondrion
2025

Prevalence of human T-cell leukemia virus type 1 associated inflammatory myopathies (HAIM) in Salvador, Brazil.

PLoS neglected tropical diseases
2025

The mitochondrial trans-2-enoyl-CoA reductase is necessary for mitochondrial homeostasis in C. elegans.

Genetics
2025

High tide or low tide: the transport and metabolism of mitochondrial nucleotides.

The Biochemical journal
2025

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

Molecular genetics and metabolism
2025

Reduced complex I activity in the retinal pigment epithelium, but not in rod photoreceptors, affects light signaling without impacting cell survival.

The Journal of biological chemistry
2025

ndufs2-/- zebrafish have impaired survival, neuromuscular activity, morphology, and one-carbon metabolism treatable with folic acid.

bioRxiv : the preprint server for biology
2025

Rewriting nuclear epigenetic scripts in mitochondrial diseases as a strategy for heteroplasmy control.

EMBO molecular medicine
2025

Extraocular features of Leber hereditary optic neuropathy: A scoping review.

Journal of biological methods
2025

Severe clinical manifestation of mitochondrial disease due to the m.3243A>T variant: a case report of early-onset, multi-organ involvement and premature death.

Journal of rare diseases (Berlin, Germany)
2025

Zagociguat prevented stressor-induced neuromuscular dysfunction, improved mitochondrial physiology, and increased exercise capacity in diverse mitochondrial respiratory chain disease zebrafish models.

Frontiers in pharmacology
2025

Corrigendum to 'Phosphodiesterase type 5 inhibition as a therapeutic strategy in primary mitochondrial disease: Evidence from patient fibroblasts and clinical observations' [Molecular Genetics and Metabolism Volume 146, Issues 1-2 (2025) Pages 109197].

Molecular genetics and metabolism
2025

"Adrift From the World": Exploring the Lived Experiences of Individuals Affected by an Inherited Optic Neuropathy in the United Kingdom-A Qualitative Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
2025

Retrospective observational study of the magnetic resonance imaging features of MPV17-related mitochondrial DNA depletion syndrome.

Pediatric radiology
2025

A novel m.14677 T > C variant in mitochondrial tRNAGlu gene causes chronic progressive external ophthalmoplegia.

Journal of human genetics
2024

Noninvasive Assessments of Mitochondrial Capacity in People with Mitochondrial Myopathies.

Muscles (Basel, Switzerland)
2025

Mitochondrial disease management through phytochemical interventions.

Molecular and cellular biochemistry
2025

Reframing primary mitochondrial disease as a sterile interferonopathy.

Molecular genetics and metabolism
2025

Small molecule oxybutynin rescues proliferative capacity of complex III-defective muscle progenitor cells.

American journal of physiology. Cell physiology
2025

Three-donor IVF prevents mitochondrial disease.

Nature medicine
2025

Phosphodiesterase type 5 inhibition as a therapeutic strategy in primary mitochondrial disease: Evidence from patient fibroblasts and clinical observations.

Molecular genetics and metabolism
2025

Hypoparathyroidism in a Child with MELAS Syndrome: A Case Report of Severe Lactic Acidosis and Symmetrical Bilateral Basal Ganglia Calcification.

International journal of endocrinology and metabolism
Ver todos os 1.205 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença mitocondrial.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença mitocondrial

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.
    Pediatric neurology· 2026· PMID 41825261mais citado
  2. COG5 deficiency disrupts cellular copper homeostasis and underlies the impaired mitochondrial OXPHOS function.
    PLoS genetics· 2026· PMID 41824529mais citado
  3. Emerging neurological and cognitive symptoms in patients with late-onset ornithine transcarbamylase deficiency: a narrative review.
    Metabolic brain disease· 2026· PMID 41824151mais citado
  4. Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease.
    Neurology. Genetics· 2026· PMID 41822038mais citado
  5. Pluripotent stem-cell-based screening uncovers sildenafil as a mitochondrial disease therapy.
    Cell· 2026· PMID 41819105mais citado
  6. Blood mtDNA markers of mitochondrial subtype and early-onset Parkinson's disease biology.
    Brain· 2026· PMID 41992946recente
  7. Comparative analysis of muscle pathologies and metabolic signaling in mouse models of mitochondrial dysfunction.
    Sci Rep· 2026· PMID 41991977recente
  8. Biallelic variants in CHCHD4 are associated with combined OXPHOS defect leading to mitochondrial disease.
    HGG Adv· 2026· PMID 41981912recente
  9. Loss of TMEM65 in mice causes mitochondrial disease mediated by mitochondrial Ca(2).
    Nat Commun· 2026· PMID 41980949recente
  10. A Nationwide Study of Pyruvate Dehydrogenase Complex Deficiency in Sweden: Epidemiology, Genotype-Phenotype Correlations, and Survival.
    Neurology· 2026· PMID 41980228recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:68380(Orphanet)
  2. MONDO:0004069(MONDO)
  3. GARD:18887(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q935710(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença mitocondrial
Compêndio · Raras BR

Doença mitocondrial

ORPHA:68380 · MONDO:0004069
Ensaios
10 ativos
MedGen
UMLS
C0751651
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades